Review

The Mechanism and Role of ADAMTS Protein Family in Osteoarthritis

Ting Li 1,2,†, Jie Peng 1,2,†, Qingqing Li 1,2,†, Yuan Shu 1,2,†, Peijun Zhu 1,2,† and Liang Hao 1,*

1 Department of Orthopedics, Second Affiliated Hospital of Nanchang University, 1 Minde Road, Nanchang 330000, China; lt15693207512@email.ncu.edu.cn (T.L.); 4203119216@email.ncu.edu.cn (J.P.); 18790135308@email.ncu.edu.cn (Q.L.); 4203120273@email.ncu.edu.cn (Y.S.); 4204119077@email.ncu.edu.cn (P.Z.)
2 Second Clinical Medical College, Nanchang University, Nanchang 330000, China
* Correspondence: ndezy07018@ncu.edu.cn; Tel.: +86-13607008562; Fax: +86-86415785
† These authors contributed equally to this work.

Abstract: Osteoarthritis (OA) is a principal cause of aches and disability worldwide. It is characterized by the inflammation of the bone leading to degeneration and loss of cartilage function. Factors, including diet, age, and obesity, impact and/or lead to osteoarthritis. In the past few years, OA has received considerable scholarly attention owing to its increasing prevalence, resulting in a cumbersome burden. At present, most of the interventions only relieve short-term symptoms, and some treatments and drugs can aggravate the disease in the long run. There is a pressing need to address the safety problems due to osteoarthritis. A disintegrin-like and metalloprotease domain with thrombospondin type 1 repeats (ADAMTS) metalloproteinase is a kind of secretory zinc endopeptidase, comprising 19 kinds of zinc endopeptidases. ADAMTS has been implicated in several human diseases, including OA. For example, aggrecanases, ADAMTS-4 and ADAMTS-5, participate in the cleavage of aggrecan in the extracellular matrix (ECM); ADAMTS-7 and ADAMTS-12 participate in the fission of Cartilage Oligomeric Matrix Protein (COMP) into COMP lyase, and ADAMTS-2, ADAMTS-3, and ADAMTS-14 promote the formation of collagen fibers. In this article, we principally review the role of ADAMTS metalloproteinases in osteoarthritis. From three different dimensions, we explain how ADAMTS participates in all the following aspects of osteoarthritis: ECM, cartilage degeneration, and synovial inflammation. Thus, ADAMTS may be a potential therapeutic target in osteoarthritis, and this article may render a theoretical basis for the study of new therapeutic methods for osteoarthritis.

Keywords: ADAMTS metalloproteinases; osteoarthritis; aggrecanase; COMP; procollagen N-proteases; extracellular matrix; synovitis; cartilage degeneration

1. Introduction

Osteoarthritis (OA) results in chronic joint pain and dysfunction syndrome characterized by the degeneration of articular cartilage, synovitis, and changes in the subchondral bone [1]. Since 2019, it has become a major source of aches, handicap, and socio-economic burden worldwide [2]. Some universal factors, including dietary intake, estrogen levels, bone mineral density, obesity, and joint relaxation are hazardous factors for osteoarthritis [3,4].

The research on OA has been uninterrupted, and some emerging therapies, such as targeting protease degeneration, elevating cartilage repair, or limiting bone remodeling, do not effectively prevent the occurrence and progression of osteoarthritis [5]. Accumulating evidence suggests that ADAMTS proteases may play an essential role in tissue morphogenesis and pathophysiological rebranding, inflammation, and vascular biology, especially in acquired diseases, such as osteoarthritis [6].

ADAMTS metalloproteinase is a secretory zinc endopeptidase comprising a signal peptide, variable-length anterior domain, a metalloproteinase domain, an integrin-like
domain, a central thrombospondin type 1 sequence repeat (TSR) motif, along with cysteine-rich, spacer domain, and auxiliary domains. The auxiliary domain determines the differences among members of the ADAMTS protein family [7]. ADAMTS protease has been implicated in several diseases, including dysgenesis, arthritis, cardiovascular disease, and cancer [8,9].

In the ADAMTS protease family, 19 members have been reported thus far, which can be further categorized into different branches: aggrecanase (ADAMTS 1, 4, 5, 8, 9, 15, and 20); procollagen N-peptidase (ADAMTS 2, 3, and 14); cartilage oligomeric matrix proteolytic enzyme (ADAMTS 7 and 12); von-Willebrand factor proteolytic enzyme (ADAMTS13), and orphan enzymes (ADAMTS 6, 10, 16, 17, 18, and 19) [6,10]. These functions are closely related to the degeneration of the ECM and cartilage in osteoarthritis, indicating that ADAMTS metalloproteinases are a potential target for the evolution of OA drugs (DMOADs); however, the current understanding of ADAMTS metalloproteinases is not comprehensive. This review aims to contribute to elucidating the mechanism of action of this family of proteins in OA and provide new perspectives on the occurrence, evolution, and insights into the development of treatment strategies for osteoarthritis.

2. Extracellular Matrix in Osteoarthritis

Extracellular matrix (ECM) primarily comprises collagen, non-collagen, elastin, proteoglycan (PG), and glycosaminoglycan (GAG), which exert key impacts on the regulation of cellular growth, differentiation, migration, and dynamic balance [11]. GAGs are classified into five groups: hyaluronan (HA), chondroitin sulfate (CS), dermatan sulfate (DS), HP/heparan sulfate (HS), and keratan sulfate (KS) [12]. CS is widely found in connective tissues of mammals such as cartilage, skin, and blood vessels. It shows clinical benefits in osteoarthritis (OA) of the finger, knee, hip joints, low back, facial joints, and other diseases due to its anti-inflammatory activity, compressive ability, and the ability to reduce pain [13]. KS is a glycosaminoglycan (GAG) type widely found in the ECM of certain tissues, such as cornea, cartilage, and bone. It acts as a hydrating and signaling agent as a component molecule in the ECM [14]. Proteoglycan is a special kind of glycoprotein, which is covalently linked by one or more glycosaminoglycans and a core protein. The predominant proteoglycan present in cartilage is the aggrecan [15]. The ECM is invariably remodeled to sustain the homeostasis of the internal environment. The cleavage of macromolecular elements in the ECM is crucial to its remodeling, which is of significance for regulating its structure and release of regulatory factors. Upon pathological remodeling of ECM, the homeostasis is maladjusted, leading to disease occurrence and progression [16].

Articular cartilage is connective tissue, composed of unique ECM, principally comprising type II, IV, VI, IX collagen and proteoglycan, as well as non-collagen elements, such as laminins and fibronectin. These elements play indispensable roles in the structure and function of cartilage [17]. According to a report, the dry weight of the ECM in cartilage is as high as 90%, thus indicating its importance [18].

2.1. Aggrecan and Aggrecanase in the ECM of Cartilage

Studies have shown that ADAMTS-1, ADAMTS-4, ADAMTS-5, ADAMTS-8, and ADAMTS-15 proteases share significant sequence homology, suggestive of similar structure and function. Therefore, these are classified as aggrecanase, which can act on aggrecan in the ECM and cleave it [19].

Aggrecan is expressed by chondrocytes, an independent proteoglycan, in the cartilage ECM. It accounts for nearly 1/3rd of the known proteins [20]. Aggrecan forms a complex with chondroitin-sulphate and keratan-sulphate, this complex binds to hyaluronic acid (HA) via a link protein, which forms a reticular structure in ECM of hyaline cartilage. This complex is scattered in the collagen network of the ECM, rendering a gel structure in cartilage; thus, endowing it with the ability to resist compression and tension, which are crucial features [21,22]. The degradation of aggrecan is an important event in early
osteoarthritis, suggesting that inhibition of the loss of condensed polysaccharides may be curative for early osteoarthritis [23,24].

The core protein of aggrecan is composed of G1, G2, and G3 domains. The G1 domain is responsible for connecting the HA, G3 forms the carboxyl terminus of the core protein and promotes glycosaminoglycan modification and product secretion. Aggrecan G3 exerts its functions mainly through its lectin-like modules encoded. Although the G2 domain has tandem repeats similar to the G1 domain, which have been proved element in the G1 domain, the G2 domain does not bind to HA. Studies have found that the G2 domain inhibits product secretion and may be involved in product quality control. The interglobular domain (IGD) is an important structure in the G1 and G2 domains. This domain contains several protease cleavage sites, including those for ADAMTS [25]. Cleavage fragments have been detected in the synovial fluid of patients with knee arthritis, and the activity of aggrecanase at the segmentation site of IGD is enhanced; thus, providing a theoretical basis for the above view [26]. Several reports suggest that aggrecan is segmented by ADAMTS proteases at one of the IGD segmentation sites, the Glu373-Ala374 bond; however, evidence also suggests that ADAMTS proteases can segment aggrecan at Glu1771-Ala1772, Glu1871-Leu1872, Glu1480-Gly1481, and Glu1667-Gly1668 bonds [27]. ADAMTS proteases exist in the ECM as an inactive proenzyme. Propeptide excision mediated by furin/proprotein converting enzyme may be a prerequisite for ADAMTS proteases to show activity [28].

2.1.1. ADAMTS-1

The structure of ADAMTS-1 containing the thrombocytopenia (TSP) type I motif was first confirmed in 1997; it binds to the ECM through acetaminoglyceride and is expressed upon inflammation and in several tumors; thus, indicating its essentiality for normal growth and development [29,30]. The expression of ADAMTS-1 is different across the stages of osteoarthritis. In normal cartilage, the expression of ADAMTS-1 is high in the superficial layer of cartilage, while in the OA cartilage, ADAMTS-1 levels are enhanced in the middle layer and osteophytes. Previous studies have shown that the expression profile of ADAMTS-1 in early versus late OA is different [31]. ADAMTS-1 cleaves aggrecan’s Glu1871-Leu1872 bond [32] (Figure 1). The catalytic activity of ADAMTS-1 depends on the covalent binding of the amino-terminal of ADAMTS-1 to α-2m, suggesting that α-2m is an inhibitor of ADAMTS-1 metalloproteinase. Additionally, ADAMTS-1 can also be inhibited by different endogenous and chemical substances [33].

2.1.2. ADAMTS-4 and ADAMTS-5

ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) are vital members of the ADAMTS metalloproteinase family, which participate in cartilage degradation and cleavage of the IGD domain’s Glu373-Ala374 bond in aggrecan [34]. ADAMTS-4 is chiefly expressed in the OA cartilage, and ADAMTS-5 is expressed in both OA and healthy cartilage tissues. Gene polymorphism in ADAMTS-5 is related to OA susceptibility, and in the experimental model of OA cartilage explants, siRNAs silencing ADAMTA-4 and ADAMTS-5 were found to slow down cartilage degeneration. Significantly enhanced ADAMTS-4 mRNA expression has been observed in experimentally induced cartilage degeneration models [35]. Normal cartilage treated with retinoic acid increased the activity of ADAMTS-4 and ADAMTS-5 but showed no abnormal changes in gene levels. These results indicate that the activities of ADAMTS-4 and ADAMTS-5 are post-transcriptionally regulated for cartilage degeneration [36,37]. Pituitary adenylate cyclase activating peptide (PACAP) is a short and evolutionary well-conserved neuropeptide and the application of it can lower the mRNA level of ADAMTS-4 and normalize its expression during oxidative stress. What is more, it is barely detectable when mechanical load and PACAP are applied concurrently [38]. Additionally, these activities are regulated by extracellular signals. IL-1α upregulates ADAMTS-5 and syndecans are involved in the activation of ADAMTS-4 and ADAMTS-5 [39]. The synergistic action of
IL-1α and Salvia miltiorrhiza's saponin upregulates ADAMTS-4 levels. IL-1β also induces the upregulation of ADAMTS-4 and ADAMTS-5, which is inhibited by ghrelin, confirming its protective action against cartilage degradation. These results may have implications for the development of OA drugs [40].

Figure 1. Structure of the ADAMTS proteases includes a signal peptide, variable-length anterior domain, metalloproteinase domain, integrin-like domain, central thrombospondin type 1 sequence repeat (TSR) motif, cysteine-rich spacer domain, and auxiliary domain. The auxiliary domain determines the differences among members of the ADAMTS protein family. The role of ADAMTS proteases is mainly reflected in the following aspects: first, ADAMTS proteases degrade various proteoglycans, especially aggrecan. Second, ADAMTS proteases cleave the amino-terminal of procollagen and promote the spontaneous assembly of procollagen into collagen fibers. Moreover, ADAMTS proteases also degrade COMP, an important non-collagen protein in the cartilage. ADAMTS regulates the release and expression levels of inflammatory factors by activating or inhibiting relevant signaling pathways; thus, completing a series of physiological function. Owing to some risk factors, including hormones, age, obesity, mechanical load, injury, and infection, these processes tend to be abnormal and decomposition is accelerated; thus, contributing to the development of osteoarthritis (OA). This figure has been created with https://app.biorender.com (accessed on 24 May 2022).

2.1.3. ADAMTS-8

The expression of ADAMTS-8 is ubiquitous in humans, showing an abundance in blood vessels and lungs. However, recent studies show that the expression profile of ADAMTS-8 is not as extensive as those of ADAMTS-4 and ADAMTS-5. Additionally, ADAMTS-8, implicated in several acquired diseases, not only exerts a strong anti-vascular effect but is an essential component in tumors. Studies have found that ADAMTS-8 is significantly downregulated in a variety of tumors and is involved in the regulation of tumor angiogenesis. In non-small cell lung cancer, the inhibition of ADAMTS-8 expression may be related to hypermethylation of promoters [41,42]. ADAMTS-8 is expressed in OA and normal cartilage tissues, and its levels are different across OA stages [43]. ADAMTS-8
can cleavage aggrecan’s Glu373-Ala374 peptide bond but the cleavage efficiency is weaker than those of ADAMTS-4 and ADAMTS-5, ADAMTS-8 [19].

2.1.4. ADAMTS-15

ADAMTS-15 has multiple roles in the pathophysiology of tumors. ADAMTS-15 can be used as a potential serum protein marker for gastric cancer [44]. The expression level of ADAMTS-15 is closely related to the prognosis of breast cancer. Expression of ADAMTS-15 in breast cancer cells reduced cell migration, which was associated with enhanced cell surface display of Syndecan-4 [45]. ADAMTS-15 plays a tumor suppressor role in prostate cancer, and the expression of ADAMTS-15 in prostate cancer is regulated by androgen [46,47].

2.2. Procollagen N-Proteolytic Enzyme in the ECM

Collagen is the primary structural component of the ECM and is used to synthesize collagen fibers for providing mechanical support to cells, tissues, and organs [48]. The collagen in articular cartilage is chiefly the type II form but other types, including types I and III, have been reported. Type I collagen is abundant in the human body and is the primary constituent of skin, bone, tendon, and blood vessels [49,50]. Mutations in the type I collagen gene cause the Ehlers–Danlos syndrome and osteogenesis imperfecta [51]. Type II collagen is the major collagen in articular cartilage and plays an important role in the ECM of chondrocytes and homeostasis. For example, in aging and osteoarthritic cartilage, type II collagen damage is observed, characterized by progressive degeneration of the triple helix structure of type II collagen and loss of the tensile properties of the cartilage. More than this, studies have also shown that the damage of type II collagen originates from chondrocytes on the surface of the joint, and gradually accumulates in the deeper layers of the cartilage as the disease progresses [52]. In addition, other studies have shown that transgenic mice lacking type II collagen have severe bone malformation, abnormal endochondral ossification and intervertebral disc dysplasia [53]. Type III collagen plays a key role in the meniscus and ECM of chondrocytes [54]. Minor collagen mainly includes types IV, VI, IX, X, XI, XII, XIII, and XIV, etc. Type X collagen is a special kind of homotrimer collagen, which is synthesized by hypertrophic chondrocytes and is found exclusively in the hypertrophic cartilage and the calcified zone of articular cartilage. Type X collagen is thought to regulate chondrocyte metabolism and interact with hypertrophic chondrocytes and maintain tissue stiffness [17]. Multiple epiphyseal dysplasia (MED) may be caused by mutations of genes encoding collagen IX, namely COL9A1 (encoding α1 chain), COL9A2 (α2 chain), and COL9A3 (α3 chain), but such mutations are not the main cause of MED [55].

Under natural physical and chemical conditions, the synthesis and decomposition of collagen and collagen fibers are balanced. Collagen first forms an isotopic or heterotopic trimer with amino and carboxyl propeptides at the center of the triple helix domain. Under the action of procollagen hydrolase, amino-propeptide and carboxyl propeptide are excised and trimers are assembled to form the collagen fibers [48,56]. However, in the pathological state, decomposition is enhanced, resulting in the loss of collagen and collagen fibers, and abnormal ECM component assembly, ultimately leading to the occurrence and progression of OA, osteoporosis, and other diseases. Procollagen C-protease and N-protease are two main procollagen hydrolases. ADAMTS-2, ADAMTS-3, and ADAMTS-14, collectively forming the procollagen N-protease, participate in several physiological processes in vivo, including blood coagulation, growth and evolution, signal transduction, and tumor progression [57]. Procollagen N-protease can specifically split the amino terminal of types I, II, and III, and the cleaved collagen through ADAMTS-2, ADAMTS-3, and ADAMTS-14, spontaneously assembles into collagen fibers. In addition, this specific cleavage is enhanced upon substrate accumulation of collagen N-proteases [56,58].
ADAMTS-2, ADAMTS-3, and ADAMTS-14

ADAMTS-2, ADAMTS-3, and ADAMTS-14, which are procollagen N-proteases, share high homology [56]. ADAMTS-2 is extensively expressed and implicated in several hereditary, acquired diseases, including tumors. ADAMTS-2 reduces endothelial cell proliferation and has angiogenic and anti-tumor molecular functions. The defect of ADAMTS-2 gene may lead to Ehlers–Danlos syndrome (Figure 1) [59,60]. The ADAMTS-3 gene was originally cloned from the human brain and is involved in the progression of some brain diseases. ADAMTS-3 plays an essential function in promoting the generation of lymphatic vessels [61,62]. Its polymorphisms are associated with susceptibility to OA. ADAMTS-2, 3, and 14 also exert essential effects for maintaining skeletal muscle integrity [63]. IL-1α, IL-6, and TGF-β upregulate the expression of ADAMTS-2 and 3 [63–65].

ADAMTS-2, 3, and 14 are upregulated in OA cartilage [66]. ADAMTS-2 processes type I procollagen, which is principally expressed in skin, while ADAMTS-3 principally processes type II procollagen in the cartilage. Therefore, some researchers believe that ADAMTS-3 may be more important for cartilage. According to experimental reports, mRNA levels of ADAMTS-3 expression in cartilage are more than double that of ADAMTS-2, in line with the above conclusion [67,68]. Taken together, the processing of ADAMTS-2, 3, and 14 for procollagen may serve cartilage self-repair, implicating their role as a protective factor against OA.

2.3. Cartilage Oligomeric Matrix Protein (COMP) Lyase in the ECM

Cartilage oligomeric matrix protein (COMP) is an extracellular matrix protein, which consists of an amino-terminal domain, 4 type II epidermal growth like repeats, 8 type III calmodulin-like repeats, and a COOH-terminal globular domain. It expresses in the cartilage, skin, and viscera, and is involved in skin and viscera fibrosis, tumor, and other diseases [69,70]. Gene mutations in COMP are associated with pseudoachondroplasia and multiple epiphyseal dysplasias and COMP is the only thrombospondin that has been associated with skeletal disorders in humans [71,72]. COMP is expressed in all layers of normal cartilage and is particularly high in the superficial layer of the OA cartilage. COMP expression is different between early- and late-stage OA. COMP can promote the synthesis of types II and XII collagen and proteoglycan, while inhibiting those of types I and X collagen; thus, maintaining the stability of these ECM components. Collectively, these indicate the significance of COMP for articular cartilage. ADAMTS-7 and ADAMTS-12 are responsible for COMP degeneration [73].

ADAMTS-7 and ADAMTS-12

The levels of ADAMTS-7 and ADAMTS-12 are elevated in the OA cartilage [74,75]. ADAMTS-7 and ADAMTS-12 not only degrade COMP in vivo but recombinant ADAMTS-12 can also degrade COMP in vitro, causing the inhibition of generation of types II and XII collagen in the ECM of OA cartilage, and that of types I and X collagen which is lowly expressed in the ECM of OA cartilage. This leads to a disorder in the ECM homeostasis [76]. Additionally, ADAMTS-7 also regulates the increase in TNF expression, leading to dyshomeostasis of the ECM and pathogenesis. Studies indicate positive feedback between ADAMTS-7 and TNF-α for regulating OA cartilage and ECM, which may become abnormal under pathological conditions [77].

2.4. ADAMTS-9 and ADAMTS-20

ADAMTS-9 and ADAMTS-20 were first reported in 2003 as isoenzymes of GON-1 [78]. ADAMTS-9 is highly expressed in embryos and normal tissues, while ADAMTS-20 expression is rare, and is detected in lung tissue and mammary glands. ADAMTS-9 is expressed in the normal cartilage and ADAMTS-20 is known to be upregulated in the OA cartilage. Both can lyse versican and aggrecan in bovine cartilage at Glu441-Ala442 and Glu1771-Ala1772, respectively [27,31,79]. Although ADAMTS-9 has a relatively weaker
activity, it may be important. Leptin and retinoic acid can induce and upregulate the expression of ADAMTS-9, respectively, and its mechanism has been elucidated [80,81].

2.5. Other ADAMTSs

ADAMTS-13 is a human hemophilia factor lyase. Lack of ADAMTS-13 can result in persistent von Willebrand factor (vWF), leading to severe thrombotic thrombocytopenic purpura [82]. ADAMTS-6 and ADAMTS-10 are homologous metalloproteinases. ADAMTS-6 is upregulated in tumors and can be used to predict unfavorable prognosis for esophageal cancer; its expression is enhanced in the OA cartilage [83,84]. Mutations in ADAMTS-10 can cause Weill–Marchesani syndrome [85]. ADAMTS-16 and ADAMTS-18 are homologous metalloproteinases. ADAMTS-16 is highly expressed in fetal, lung, kidney, and other organ tissues, along with human cartilage and synovial membrane. ADAMTS-18 is indispensable for organ evolution, reproductive angiogenesis, coagulation, inflammation, and tumor formation [86,87]. A few studies on ADAMTS-17 suggest that the occurrence of some genetic diseases may be related to mutations in ADAMTS-17. ADAMTS-19 is a potential marker of ovarian function [87]. At present, the underlying mechanism of ADAMTS metalloproteinases’ action in OA remains unclear and is not, therefore, expounded here. In Table 1, we summarize the basic information on ADAMTS proteases.
Table 1. ADAMTS protein family members, gene loci, tissue distributions, pathological effects, and Mendelian diseases (TBD: to be determined).

| Gene Locus | ADAMTS | Molecular Weight of Full-Length Protein (KDa) | Tissue Distribution | Substrate/Target | Biological or Pathological Role | Disease Resulting from Mutations in Human ADAMTS Genes | Gene Polymorphism | Reference |
|------------|---------|-----------------------------------------------|---------------------|------------------|-------------------------------|-----------------------------------------------------|------------------|----------|
| 21q21      | 1       | 105                                           | Heart, bronchial epithelial cells, fetal lung, liver, aorta, smooth muscle, colon, uterus, kidney, adrenal gland, adipocytes, placenta, uterus, ovary, prostate, bladder, spinal cord, ciliary ganglion, olfactory bulb, breast stromal fibroblasts, and myoepithelial cells | Aggrecan, versican, syndecan 4, TFPI-2, semaphorin 3C, nidogen-1, – 2, desmocollin-3, dystroglycan, mac-2, gelatin (denatured collagen type I), amphiregulin, TGF-α, heparin-binding EGF, VEGF | Cancer (both pro- and antitumorigenic/metastatic), anticoagulant, promote egg maturations and excretion, associated with oral diseases | ADAMTS-1 knockout mice had abnormal body weight and renal insufficiency | TBD            | [88–91]  |
| 5q35       | 2       | 135                                           | Breast stromal fibroblasts adipocytes, heart, lung, liver, kidney, bladder, aorta, smooth muscle, skeletal muscle, tendon, bone, skin, retina, superior cervical ganglion, uterus, placenta | Fibrillar procollagens types I, II, III, and V N-propeptide | Ehlers–Danlos syndrome type VIIc, dermatosparaxis (in sheep and cattle) Ehlers-Da leads to a variety of skin lesions and systemic symptoms, related to the pathogenesis of liver cirrhosis and vascular diseases, playing a key role in the occurrence and development of tumors | Ehlers–Danlos syndrome (EDS), dermatosparaxis type or type VII/Geleophysic dysplasia 1 | 676, 844 site T to C | [6,48,60,92–97] |
| 4q21       | 3       | 140–150                                        | CD105+ endothelial cells, CD34+ cells, heart, lung, pineal gland, cartilage, bone, skeletal muscle, tendon, breast myoepithelial cells, placenta, brain | Fibrillar procollagen type II N-propeptide, biglycan, pro-VEGF-C, reelin | Lymphangiogenesis, placental angiogenesis, brain functions, playing a key role in the occurrence and development of tumors | Hennekam lymphangiectasia-Lymphedema syndrome 3 | Biallelic dislocation mutation 73, 414, 196 sites A to G; 73, 188, 804 sites A to G | [48,61,62,67,95,97–99] |
| 1q23       | 4       | 90                                            | Ovary, adrenal cortex, ciliary ganglion, trigeminal ganglion, brain, spinal cord, retina, pancreas (islets), heart, fetal lung, bladder, uterus, skeletal muscle, breast myoepithelial cells, synovial fluid | Aggrecan, versican, neurocan, reelin, biglycan, brevican, matrilin-3, a2-macroglobulin, oligomeric matrix protein (COMP) | Multiple diseases such as arthrtsis, amyotrophic lateral sclerosis, renal fibrosis and other renal diseases, atherosclerosis and vascular diseases, reproductive function, and nervous system injury | Ectopia lentis et pupillae Ectopia lentis, isolated, autosomal recessive | Nonsense mutation 11: c.1785T→G (p.y595X); c.767_786del20 | [100–108] |
| 21q21      | 5 (11)  | 73                                            | Adipocytes, bladder, uterus, placenta, breast myoepithelial cells | Aggrecan, versican, reelin, biglycan, matrilin-4, brevican, a2-macroglobulin | Osteoarthritis, cancer (antitumor, anti-angiogenesis), amyotrophic lateral sclerosis, renal diseases like renal fibrosis, atherosclerosis and vascular disease, injury of reproductive system and nervous system | TBD | TBD | [100,102–106,109,110] |
| 5q12       | 6       | 116                                           | Superior cervical ganglion, trigeminal ganglion, appendix, heart, breast myoepithelial cells | TBD | TBD | TBD | [110] |
| Gene Locus | ADAMTS | Molecular Weight of Full-Length Protein (KDa) | Tissue Distribution | Substrate/Target | Biological or Pathological Role | Disease Resulting from Mutations in Human ADAMTS Genes | Gene Polymorphism | Reference |
|------------|---------|-----------------------------------------------|---------------------|-----------------|--------------------------------|---------------------------------------------|-----------------|----------|
| 15q24      | 7       | 182                                           | Trigeminal ganglion, adrenal cortes, kidney, liver, pancreas, heart, smooth muscle, skeletal muscle, intervertebral disc, breast stromal fibroblasts | Cartilage oligomeric matrix protein (COMP) | Coronary artery disease (smooth muscle cell migration) participates in development and vascular remodeling, tumorigenesis and migration, spontaneous abortion | TBD | TBD | [110–117] |
| 11q25      | 8       | 80                                            | Skeletal muscle, heart, lung, liver, superior cervical ganglion, adrenal cortex, breast stromal fibroblasts and luminal epithelial cells, placenta, brain | Aggrecan | Anti-angiogenesis, tumor | TBD | TBD | [118] |
| 3p14       | 9       | 217                                           | Heart, lung, kidney, pancreas, colon, ovary, skeletal muscle, dorsal root ganglion, capillary endothelial cells, breast myoepithelial cells | Aggrecan, versican | Cancer, anti-apoptotic and antitumor. As a diagnostic marker of vascular diseases, rheumatoid arthritis | TBD | TBD | [6,119–122] |
| 19p13      | 10      | 121                                           | Heart, lung, liver, pancreas, kidney, brain, placenta, CD8+ T-cells, brain, uterus, breast stromal fibroblasts | Fibrillin-1 | Weill–Marchesani syndrome | Weill–Marchesani syndrome | Nonsense mutation R237X; Shear mutation 190 + 1G→A, 810 + 1G→A | [123–125] |
| 5q35       | 12      | 178                                           | Liver, bone marrow, intervertebral disc, atrioventricular node, smooth muscle, breast stromal fibroblasts, and myoepithelial cells | Oligomeric matrix protein (COMP) | Cell adhesion, cancer, allergic asthma, colitis, symptomatic arthritis, regulate and restore the progression of inflammation, also exacerbate inflammation | TBD | TBD | [6,126,127] |
| 9q34       | 13      | 190                                           | Heart, lung, liver, pancreas, kidney, brain, placenta, CD371+ early erythroid cells, endothelial cells, thyroid, breast myoepithelial cells | von Willebrand factor | Thrombotic thrombocytopenic purpura, congenital/Upshaw–Schulman syndrome | Thrombotic thrombocytopenic purpura, congenital/Upshaw–Schulman syndrome | 2074 C to T(R692C) 3638G to A(C1213Y) 2376 to 2401 defect | [6,128–132] |
| 10q21      | 14      | 134                                           | Fibroblasts, lung, liver, prostate, retina, placenta, thalamus, bone marrow, fetal thyroid, adipocytes, cerebellum, bone, skin, breast myoepithelial, and luminal epithelial cells | Fibrillar procollagen type I N-propeptide (pNα1 and pNα2 chains) | Related to multiple sclerosis and female osteoarthritis | TBD | TBD | [6,48,133–136] |
| 11q25      | 15      | 103                                           | Colon, brain, heart, uterus, musculoskeletal system, breast myoepithelial cells | Aggrecan, versican | Cancer (anti-tumor metastasis, anti-angiogenesis), playing a role in liver diseases, high expression in prostate cancer, androgen dependence | TBD | TBD | [31,45,133,137] |
| Gene Locus | ADAMTS | Molecular Weight of Full-Length Protein (KDa) | Tissue Distribution | Substrate/Target | Biological or Pathological Role | Disease Resulting from Mutations in Human ADAMTS Genes | Gene Polymorphism | Reference |
|------------|---------|-----------------------------------------------|--------------------|-----------------|-------------------------------|------------------------------------------------|-----------------|----------|
| 5p15       | 16      | 136                                           | Brain, ovary, breast myoepithelial cells, aorta | TBD             | Hypertension                  | TBD                                           | c.2458_2459insG (p.E820GfsX23), c.1721+1G> C > T (Q254X) | [6,133] |
| 15q24      | 17      | 121                                           | Ovary, breast myoepithelial cells | TBD             | Weill–Marchesani-like syndrome | Weill–Marchesani-like syndrome | c.2065G > T, p.Glu689X, c.97C > T((p.Gln33X)) | [101,133,139,140] |
| 16q23      | 18      | 135                                           | Endothelium, prostate, brain, ciliary ganglion, heart, skin, breast myoepithelial cells | TBD             | Microcornea, myopic chorioretinal atrophy and telecanthus | Microcornea, myopic chorioretinal atrophy and telecanthus | c.2065G > T, p.Glu689X, c.97C > T((p.Gln33X)) | [101,133,139,140] |
| 5q31       | 19      | 134                                           | Dorsal root ganglion, breast myoepithelial cells | TBD             | TBD                           | TBD                                           | TBD | [6] |
| 12q12      | 20      | 215                                           | Heart, lung, pancreas, prostate, testis, ovary, placenta, brain, appendix, liver, skeletal muscle, pituitary, trigeminal ganglion, breast myoepithelial cells | Versican         | Colorectal cancer, involved in some malignant tumors | TBD                                           | TBD | [141,142] |
3. ADAMTS and Cartilage Degeneration in OA

Cartilage is a special connective tissue and can be classified into hyaline cartilage, fibrocartilage, and elastic cartilage based on the differences in the intercellular substance. Articular cartilage is principally hyaline cartilage and is the main load-bearing cartilage in adults. It only contains chondrocytes, which together with the pericellular matrix (PCM) form the "cartilage" [17,143]. Cartilage can be divided into the surface, cambium, radiating, and calcified layers, which serve functions of load-bearing, lubrication, and force absorption, while supporting and protecting joints [144].

Biochemical and mechanical functions of chondrocytes depend on the integrity of chondrocytes, PCM, and ECM [145]. Mechanical load is a vital factor affecting the physical and chemical properties of articular cartilage. Moderate mechanical stimulation leads to chondrocyte hypertrophy and normal metabolism, thus promoting the formation of subchondral bone; reduced mechanical stimulation leads to chondrocyte atrophy and degeneration; and excessive mechanical stimulation leads to cartilage collagen network damage and proteoglycan loss, resulting in irreversible cartilage destruction [146]. In OA, various metabolic and biomechanical factors act on chondrocytes, which not only damage the chondrocytes, leading to a loss of matrix molecules but also cause abnormal proliferation, secretion, and hypertrophy, resulting in disruption of homeostasis between decomposition and synthesis of ECM. Catabolic processes predominate during these pathological changes. Chondrocyte hypertrophy leads to the surroundings becoming mineralized. Additionally, the elastic properties of cartilage begin to change and calcify and harden. Although hypertrophic changes in chondrocytes are required in bone growth and development, when receiving high mechanical stress, this leads to chondrocyte apoptosis. However, it is not clear whether abnormal hypertrophy of chondrocytes is beneficial or harmful [147]. Over time, cartilage degrades progressively and interacts with the subchondral bone; thus, accelerating the progression of OA. Articular cartilage contains no blood vessels or nerve tissues and has very low regeneration potential. Even though human bone stem cells have been identified, the overall repair of damaged cartilage remains markedly low, with discrepancies depending on the individual and age [148,149].

3.1. Aggrecanase in Articular Cartilage

Aggrecan contains several glycosaminoglycan chondroitin sulfate side chains. Aggrecan has a high-density negative charge owing to the carboxyl and sulfate functional groups in its side chains. The side chain of glycosaminoglycan determines the physicochemical properties of aggrecan [21]. The negatively charged gel structure formed by aggrecan is dispersed in the collagen fiber network, absorbing and combining with abundant water, increasing the expansion pressure, and providing compressive deformation resistance and shock absorption in the cartilage [21,22]. Additionally, hyaluronic acid and chitosan bind to the cell surface to sustain chondrocyte spacing and the structure of cartilage [23]. Aggrecan also enhances chondrocyte proliferation and bone marrow mesenchymal stem specialization [150]; thus, demonstrating its importance in the articular cartilage. Aggrecan concentration also affects articular cartilage, showing different behaviors at four concentrations [22]. This confirms that an adequate concentration can sustain the normal physiological functions of aggrecan. This phenomenon may be linked to the dissimilar density of negative charges at different concentrations.

The primary role of ADAMTS-1, 4, 5, 8, and 15 in articular cartilage is to cleave aggrecan, which has been proved to be the most effective segmentation for the interglobular domain of IGD [151]. The synthesis and degradation of aggrecan are in a dynamic balance. Under pathological conditions, the degradation of aggrecanases results in accelerated aggrecan loss, which increases the sensitivity of articular cartilage to protease and mechanical stimulation; thus, enhancing cartilage degeneration and occurrence, and progression of OA [24]. The inhibition of glucase activity in OA may improve the ECM stability and delay cartilage degeneration. ADAMTS-4 and ADAMTS-5 should be the main focus of targeted glucase therapy due to the weaker activities of other glucases. Un-
der specific circumstances, the cleavage of aggrecan by aggrecanase is reversible but the underlying mechanism remains elusive. Elucidating this mechanism may help develop new drugs [152].

Additionally, cartilage degeneration is related to subchondral bone changes. In the early stage of osteoarthritis, subchondral bone remodeling is increased, while bone resorption and bone formation are increased in the late stage. Osteoblasts play an important role in bone remodeling [153,154]. Changes in signaling between subchondral osteoblasts and chondrocytes of articular cartilage produce abnormal levels of metalloproteinases (ADAMTS), which may cause osteoarthritis [154]. ADAMTS-1 can promote the proliferation of osteoblasts by inducing the degradation of type I collagen and play a role in the initiation of bone reconstruction, while ADAMTS-1, ADAMTS-4 and ADAMTS-5 can promote the differentiation of osteoblasts [90,155], thereby affecting the development of OA.

3.2. Procollagen N-Protease in the Articular Cartilage

The main scaffold of cartilage ECM is collagen fiber. Collagen fibers are arranged parallel to the surface of the joint, and this arrangement is the basis of the tensile function and sheer force of collagen fibers [156].

Collagen fibers and aggrecan macromolecular aggregates together form a support network, and this is crucial to the morphology and function of support and protection of cartilage cells. Proper mechanical loading contributes to the health of articular cartilage [157]. However, mechanical load exceeding the threshold results in cartilage wear and damage. The damage may initially result from microscopic cracks in the surface of the cartilage, which impair its mechanical and biomechanical qualities [158,159]. Collagen fibers determine the morphology of cracks on the surface of damaged articular cartilage [160]. If the factors exceeding the loading threshold are not relieved, the speed and degree of cartilage damage may be aggravated over time, resulting in degeneration of type II collagen and breakage of collagen fibers, which may lead to the occurrence and progression of OA. The mechanical properties and arrangement of collagen fibers in mature and immature cartilage are prominently different [160], showing that collagen fibers are constantly reconstructing their structure to adapt to the functional requirements of the articular cartilage at diverse stages of chondrogenesis. Together, these results indicate the indispensable role of collagen fiber in the cartilage.

Collagen and collagen fiber formation by crosslinking provide tensile strength for the cartilage, whereby type II collagen plays a key role. Type II collagen determines the life span of the articular cartilage to a certain extent [161]. ADAMTS-2, 3, and 14 are responsible for degrading of types I, II, III, and V procollagen to form specific collagen fibers. Additionally, types I, II, and X collagen are involved in bone formation and cartilage ossification, suggesting that ADAMTS-2, ADAMTS-3, and ADAMTS-14 also are essential for bone formation and endochondral ossification. Elucidating the underlying mechanism will, therefore, be useful for comprehending OA [156]. It is speculated that if the activities of ADAMTS-2, ADAMTS-3, and ADAMTS-14 are enhanced in OA, the formation and remodeling of collagen fibers to repair the damaged fiber network may occur; thus, delaying the progression of OA and improving clinical symptoms.

3.3. COMP Lyase in Articular Cartilage

COMP and other collagen, including type XII collagen, give tensile capacity and enhance the mechanical power of the ECM of the cartilage [162]. COMP contributes to cartilage formation, which depends on the interaction between COMP and granulopithelial protein precursor (GEP). COMP induces the generation of type XII collagen [162,163]. In OA, upregulated expression of ADAMTS-7 and ADAMTS-12 result in COMP loss [73]. Previous studies have also ascertained that in the progression of OA, COMP expression in the early and late stages in various parts of cartilage, shows discrepancy [164], which may be explained as COMP’s attempt to repair the damaged cartilage. COMP can enhance chondrogenic differentiation of human bone marrow stem cells [165]. In addition, COMP
can be used as a marker of OA, RA, and a variety of fibrotic diseases. Synovial fluid and serum COMP levels reflect joint degeneration and can be used as a long-term prognostic marker of joint injury [162]. This manifests the essential role of COMP in cartilage and its prognostic value. ADAMTS-7 and ADAMTS-12 not only lyse COMP and destroy the cartilage structure but also effectively inhibit its differentiation. ADAMTS-7 can also upregulate the expression of TNF and further mediate cartilage degeneration [166,167].

Intriguingly, ADAMTS-7 and ADAMTS-12 are downstream molecules of parathyroid hormone-associated protein (PTHrP), which regulate chondrocyte differentiation rate and negatively mediate the endochondral bone [167,168]. Inhibition of ADAMTS-12 not only inhibits COMP decomposition but also increases osteoclast formation [167]. Thus, ADAMTS-7 and 12 are not only necessary for cartilage degeneration in OA but also in mediating changes in the subchondral bone.

4. ADAMTS and Inflammation in OA

Synovial inflammation is a significant feature of OA. The synovial membrane contains metabolically active synovial cells that render nutrition and support to articular cartilage through the synovial fluid and arthrosis space [169]. Many OA patients have synovial thickening or fluid accumulation in their joints, resulting in redness, swelling, heat, pain, and other symptoms [170]. This inflammation may be an adaptive reaction to joint injury. The degree of inflammation in OA is lesser than that of rheumatoid arthritis but in the absence of obvious inflammation, chondrocytes themselves or the surrounding tissues also produce pro-inflammatory factors and diversely regulate aggrecanase and collagenase [169].

Inflammatory mediators involved in OA include cytokines, chemokines, prostaglandins, and transforming growth factors, which are essential for cartilage homeostasis [171]. When dysregulation of homeostasis promotes cartilage damage, it begins to degrade, and degradation products are released into the synovial fluid; thus, stimulating the release of pro-inflammatory cytokines and some proteases, which further aggravate the damage. Thus, cartilage damage and synovial inflammation form a vicious positive feedback loop [169,172].

Obesity also boosts OA [173]. Obesity enhances the mechanical load of articular cartilage, resulting in its damage; ADAMTS protease is involved in this process. Higher inflammatory mediators, such as adipokines, are released from the fat tissues of obese individuals. Tumor necrosis factor-α (TNF-α), Interleukin (IL)-1, and IL-6 produced by macrophages are also important sources of inflammatory mediators [174]. These inflammatory factors activate chondrocytes, and upregulate ADAMTS proteases and MMPs; thus, facilitating cartilage matrix degeneration and bone resorption [175] (Figure 2). These results suggest the interaction between ADAMTS proteases, synovitis, and OA. Herein, we emphasize the interaction between several specific inflammatory mediators and ADAMTS proteases in OA, to provide gist for developing new therapeutic methods and countermeasures.

4.1. Tumor Necrosis Factor-α (TNF-α)

The effect of TNF-α on ADAMTS metalloproteinases is primarily manifested in ADAMTS-4, 5, and 7. TNF-α is deemed to be the most valid anti-tumor effector factor which drives inflammatory cascade reactions [176]. TNF-α induces the generation of PG, IL-1, IL-6, IL-8, nitric oxide synthase (NOS), and cyclooxygenase-2 (COX-2). Furthermore, the expression of MMPs, ADAMTS-4, and ADAMTS-5 are upregulated, while the formation of proteoglycan and type II collagen is inhibited; synergistic action with these cytokines, especially IL-1, results in cartilage destruction and OA [177].

TNF-α activates the nuclear factor kappa-B (NF-κB) signaling pathway, which in turn advances the generation of pro-inflammatory cytokines, forming a positive feedback loop and exacerbating the degeneration of articular cartilage [178] (Figure 2). TNF-α also affects ADAMTS-7, which upregulates the expression of ADAMTS-7 at the gene and transcriptional levels; it also advances the synthesis of TNF-α, indicating that ADAMTS-7 and TNF-α form a positive feedback loop in OA. This circuit accelerates COMP degradation and the progression of OA [166].
Various substances inhibit the inflammatory effects of TNF-α. Ivabradine and Shikimic-acid (SA) significantly inhibit TNF-α-induced expression of ADAMTS-4, ADAMTS-5, and MMPs, along with the loss of type II collagen and aggrecan at the gene and transcription levels. SA also inhibits the activation of the NF-κB pathway [177,179].

Figure 2. The development of OA is mediated by inflammatory factors and ADAMTS. TNF-α induces the production of prostaglandins (PG), IL-1, IL-6, IL-8, nitric oxide synthase (NOS), and cyclooxygenase-2 (COX-2); upregulates the expression of matrix metalloproteinase and ADAMTS-4, ADAMTS-5; and inhibits the production of proteoglycan and type II collagen, resulting in cartilage destruction and OA. This process is also affected by the IL1-β/MAPK pathway. COMP also plays an important role in the occurrence of OA. In particular, TNF-α, vasoactive intestinal peptide (VIP) can directly act on COMP, thus affecting the progression of OA. The PACAP is also evidenced to exert an anti-inflammatory function in OA. The expression of ADAMTS-7 is upregulated at the gene and transcriptional levels by TNF-α, and ADAMTS-7 further increases TNF-α levels, resulting in a positive feedback loop, accelerating the degradation of COMP and the onset and progression of OA. This process is mainly inhibited by the antibody against ADAMTS. Interleukin and growth factors are also implicated in the development of OA. For example, IL-1β can increase the synthesis of various proteolytic enzymes, such as ADAMTS metalloproteinases and matrix metalloproteinases (MMPs) and inhibit the synthesis of proteoglycan. TGF-β not only increases the ADAMTS-4 mRNA levels but also stimulates the expression of ADAMTS-16 in chondrocytes, which has important regulatory significance for the progression of OA.

4.2. Interleukins

The impact of interleukins, including IL-1, IL-6, IL-8, and IL-10, are principally reflected in ADAMTS-4 and ADAMTS-5 in OA. Among them, in OA, IL-1 is the most valid pro-inflammatory cytokine which has an extensive range of effects in vivo [180,181].

IL-1 includes IL-α and IL-β. IL-1α is a bifunctional cytokine present in resting cells under physiological conditions. IL-1β can upregulate the expression of most cytokines,
including COX-2, NO, TNF-α, prostaglandin E2 (PGE2), and IL-6 through the mitogen-activated protein kinase (MAPK) pathway \[182\]. It also increases the synthesis of ADAMTS proteases and MMPs and inhibits the synthesis of proteoglycan \[183\] (Figure 2). Additionally, TNF-α and IL-1β induce COMP degeneration. IL-1β also activates nuclear transcription factors to further stimulate the secretion of pro-inflammatory mediators \[184\].

Specific antibodies against ADAMTS-7 and ADAMTS-12 and siRNA silencing inhibits COMP degeneration induced by TNF-α and IL-1β, hinting that IL-1 may have synergistic effects with TNF-α \[185\]. In addition to specific antibodies, some chemicals inhibit the inflammatory effects of IL-1. Ellagic acid (EA) and Isofraxidin (IF) inhibit IL-1β induced COX-2, NO, TNF-α, PGE2, and IL-6 downregulate MMP-13 and ADAMTS-5, and increase type II collagen and chitosan \[186\]. Thus, EA can delay the progression of OA.

IL-6 is a direct target of NF-κB \[187\]. IL-6 can stimulate chondrocytes, which is manifested by decreased proteoglycan content and enhanced expression of ADAMTS-4 and ADAMTS-5. This is accomplished through transcriptional activator 3 (STAT3) and extracellular signal-regulated kinase (ERK) pathways \[188\].

The physiological function of IL-10 is to block inflammatory responses and regulate the proliferation and differentiation of various immune cells \[189\]. IL-10 can significantly alleviate the mechanical damage to articular cartilage, reduce aggrecan degradation, and inhibit the expression of ADAMTS-4 and other proteases \[190\]. This indicates that IL-10 may have protective effects on articular cartilage.

### 4.3. Transforming Growth Factor (TGF)

Transforming growth factors include TGFα and TGF-β. TGFα is a member of the epidermal growth factor (EGF) ligand family, which has a pivotal role in cellular proliferation, differentiation, and wound healing. In OA, it accelerates the cleavage of type II collagen and aggrecan and alters the articular chondrocyte phenotype \[191\].

Transforming growth factor β (TGF-β), a member of the TGF-β superfamily, is critical in inflammatory cascades mediated by the TNF-α, IL-1, and TGF-β pathways \[192\] (Figure 2). TGF-β stimulates cartilage matrix proliferation, increases the mRNA levels of ADAMTS-4, and upregulates the expression of ADAMTS-4, which is co-regulated by TGF-β-associated kinase 1 (TAK1) and the NF-κB signaling pathway \[40,193\]. Moreover, TGF-β also stimulates the expression of the ADAMTS-16 in chondrocytes \[86\]. The effects of TGF-β are inhibited by losartan. Losartan may thus be a potential candidate for OA treatment \[194\].

### 4.4. Others

Leptin is a small-glycosylated peptide hormone produced by white adipose tissue and induces the gene expression of ADAMTS-4, ADAMTS-5, and ADAMTS-9 through the MAPK and NF-KB signaling pathways. After leptin treatment, the expression of ADAMTS-4 and ADAMTS-5 is significantly increased, and the loss of proteoglycan in articular cartilage is severe \[80,175,195\]. Therefore, leptin may have a catabolic influence on articular cartilage, and this influence is likely to have adverse effects.

NO enhances the activity of ADAMTS-4 and ADAMTS-5 at the transcriptional level, and synergistically accelerates the degradation of cartilage matrix with TNF-α; thus, promoting the progression of OA \[196\]. Vernonia amygdalina (VA) can reduce the release of NO \[197\].

VIP and corticotropin-releasing factor (CRF) can downregulate the expression of ADAMTS-4, 5, 7, and 12 in articular cartilage, and reduce aggrecan GAG side chain and COMP degradation \[198\]. Thus, VIP and CRF exert potential protective effects on OA articular cartilage.

Prostaglandin D2 (PGD2) has protective and anti-inflammatory properties in joints. It can increase the expression of type II collagen and aggrecan, while inhibit chondrocyte apoptosis and several inflammatory responses \[199\]. However, PGE2 inhibits the synthesis of proteoglycan in the articular cartilage and promotes the degradation of the cartilage matrix. PGE2 also stimulates IL-1 to enhance the induction of ADAMTS-5, a risk factor for OA \[200,201\].
5. ADAMTS and Fibrosis

At present, the fibrotic effects of ADAMTS in vivo are mostly concentrated in the liver, kidney, and heart. Studies showed that the collagen deposition rate of ADAMTS-2-deficient mice was slower than that of wild mice, that is, ADAMTS-2 reduced the degree and stability of liver fibrosis in mice [202]. In addition, treatment with carbon tetrachloride-induced hepatic fibrosis in mice, also resulted in increased expression of ADAMTS-5, -9, -15, -20, TNF-α, and TGF-β in the liver [203]. ADAMTS-16 activates cardiac fibroblasts and promotes cardiac fibrosis and heart failure. TGF-β is a strong inducer of cardiac hypertrophy. ADAMTS-16 promotes cardiac fibrosis and cardiac hypertrophy by activating the LAP-TGF-β signaling pathway through RRFR motifs, resulting in the cleavage of the LAP domain of LAP-TGF-β and the release of TGF-β [204]. ADAMTS-18 deficiency causes spontaneous submandibular salivary gland fibrogenesis and fibrosis in adult mice [205]. ADAMTS-1 is critical for kidney development, and lack of ADAMTS-1 may lead to renal fibrosis and dysplasia in mice [206]. It is reported that mechanical stress causes fibrosis of cartilage, the process associated with TGF-β and connective tissue growth factor (CCN2). During the experiment, excessive mechanical stimulation increased the expression of ADAMTS-5, collagen I, and collagen III genes, and decreased the expression of collagen II. This process relies on the TGF-β1/CCN2/Integrin-α5β1 signaling pathway, and disruption of this signaling pathway can alleviate chondrocyte fibrosis [207]. In addition, degeneration of intervertebral discs is closely related to fibrosis. This may be because ADAMTS degrades important components of ECM in the process of disc degeneration. For example, ADAMTS-8 degrades GAG and HA, leading to dysfunction of the most important ECM and accelerating disc degeneration [208]. Secondly, the expression of the ADAMTS gene may increase the risk of stiffness post total knee replacement [209].

6. Intervention and ADAMTS in OA

Palliative therapy and surgical treatment are currently adopted in clinical practice. Drugs chiefly include steroids or non-steroidal anti-inflammatory compounds, which have analgesic and anti-inflammatory effects [210,211]. Non-drug therapy includes education, self-management, exercise, and weight loss [210,212]. Surgical therapy mainly comprises joint replacement and chondroplasty [149,213,214]. These methods are effective in the short term and relieve pain but in the long-term, the disease may worsen [128,215]. OA modification drugs (DMOADs) are being developed but an effective intervention is lacking. ADAMTS proteases have been a target of drug therapy for OA, including targeting ADAMTS to stimulate chondrocytes, reduce proteoglycan and collagen loss, advance cartilage repair, and restore ECM homeostasis.

However, current studies on the targeted inhibition of ADAMTS remain unsatisfactory, due to the lack of specificity of targeted inhibitors. ADAMTS proteases are not only expressed in joints but also other tissues. These are implicated in hereditary and acquired diseases and participate in the occurrence and development of tumors. Extensive inhibition of ADAMTS can cause serious complications in other tissues and organs. Nineteen subtypes of ADAMTS proteases are classified into different branches and play various roles in articular cartilage. In this review, we describe that ADAMTS-1, 4, 5, 8, 15, and ADAMTS-7, 12 are potential risk factors for OA, while ADAMTS-2, 3, and 14 show protective effects on articular cartilage. While inhibiting risk factors, targeted inhibitors also inhibit protective factors, which may have adverse effects on the articular cartilage. Additionally, different subtypes of ADAMTS in the same clade have similar structures but show some differences, resulting in slight variations in the functions of each subtype. However, homology exists between different isoforms; thus, necessitating higher specificity of the targeted inhibitors. In Table 2, we summarize the intervention drugs and inhibitors for ADAMTS that have been investigated thus far.
Table 2. Some drugs and inhibitors of ADAMTS (TBD: to be determined).

| ADAMTS Material | Endogenous Inhibitor | Synthetic Inhibitor | Reference |
|------------------|-----------------------|---------------------|-----------|
| TIMP-2 TIMP-3    |                       |                     |           |
| TIMP-3 TIMP-3    | Tissue inhibitor of metalloproteinase | Binding inhibition | 1,10-phenanthroline | EDTA BB-94 | Organic small molecule | Binding inhibition | Urin recognition site (RX(K/R)R) (33, 34) | [27] |
| TIMP-3 Cu²⁺ α₂ macroglobulin Faplin | Tissue inhibitor of metalloproteinase | Binding inhibition | Sulfated glycosaminoglycans associated with ECM and cell surfaces | Boundary zinc blinding zone | TBD | [216–219] |
| TIMP-3 TIMP-3 Cu²⁺ | Tissue inhibitor of metalloproteinase | Binding inhibition | Sulfated glycosaminoglycans associated with ECM and cell surfaces | TBD | [218] |
| TIMP-3 TIMP-3 α₂ macroglobulin Matrix protein CCN1 | Tissue inhibitor of metalloproteinase | Glu1480-Gly1481 bond | Cin-1(5)(R)-amino-2-indanol-based | 691GRGHR Metformin | Selective action Organic small molecule | Water bridging, ring rigidity, pocket size, and shape | [217,220,221] |
| PTH1-34 TIMP-3 Matrix protein CCN1 | Tissue inhibitor of metalloproteinase | Glu1480-Gly1481 bond | Cin-1(5)(R)-amino-2-indanol-based | TGF-β/CCN1 IGF/IGFBP | Selective action Organic small molecule | Water bridging, ring rigidity, pocket size, and shape | NF-κB |
| α₂ macroglobulin | Enzyme | Binding inhibition | TGF-β/CCN1 | Losartan | Selective action Organic small molecule | Water bridging, ring rigidity, pocket size, and shape | [217,220,221] |
| TIMP-3 TIMP-3 α₂ macroglobulin PTH1-34 | Tissue inhibitor of metalloproteinase | Glu1480-Gly1481 bond | Cin-1(5)(R)-amino-2-indanol-based | YESDVM690 4,5-Dicaffeoylquinic Acid | Selective action Organic small molecule | Water bridging, ring rigidity, pocket size, and shape | NF-κB |
| TIMP-3 TIMP-3 α₂ macroglobulin PTH1-34 | Enzyme | Binding inhibition | Glycoconjugated arylsulfonamide | Losartan | Selective action Organic acid | Signal conditioning | NF-κB |
| TIMP-3 TIMP-3 α₂ macroglobulin PTH1-34 | Enzyme | Binding inhibition | Glycoconjugated arylsulfonamide | Losartan | Selective action Organic acid | Signal conditioning | NF-κB |
| TIMP-3 TIMP-3 α₂ macroglobulin PTH1-34 | Enzyme | Binding inhibition | Glycoconjugated arylsulfonamide | Losartan | Selective action Organic acid | Signal conditioning | NF-κB |
| TIMP-3 TIMP-3 α₂ macroglobulin PTH1-34 | Enzyme | Binding inhibition | Glycoconjugated arylsulfonamide | Losartan | Selective action Organic acid | Signal conditioning | NF-κB |
### Table 2. Cont.

| ADAMTS | Endogenous Inhibitor                  | Synthetic Inhibitor | Reference |
|--------|---------------------------------------|---------------------|-----------|
| 7      | TIMP-4                                | Active site zinc    | Granulin-epithelin precursor | Binding inhibition | Carboxy-terminal TSR motifs of ADAMTS7 and 12 | [76,217,227,228] |
|        | GEP                                   | C-terminal thrombospondin motifs | JG23 | Organic acid | Binding inhibition | IC, cut | Combined with zinc ion |
| 8      | TBD                                   | LIPUS               | Pulse | Electotherapy | ZNT-9 | [229–231] |
| 12     | TIMP-4                                | Active site zinc    | Granulin-epithelin precursor | Protein | Binding inhibition | Carboxy-terminal TSR motifs of ADAMTS7 and 12 | [76,217,227,228] |
|        | α2-M                                  | C-terminal thrombospondin motifs | [218] |
|        | GEP                                   | Protein             | TBD | [218] |
| 14     | TIMP-3                                | Sulfated glycosaminoglycans associated with ECM and cell surfaces | TBD | [218] |
|        | Cu^{2+}                               | Bound zinc blinding zone | | | | |
7. Conclusions

In this review, we highlighted the role and mechanism of ADAMTS proteases in all aspects of OA from various dimensions, and comprehensively described the importance of the ADAMTS protein family in the intervention and therapy for OA. OA has placed a heavy burden on the economy and health worldwide, but therapy and interventions remain challenging. It is anticipated that this article can provide new ideas for developing OA-related intervention and treatment strategies.

**Author Contributions:** Conceptualization, L.H., T.L. and J.P.; writing—original draft preparation, T.L. and J.P.; writing—review and editing, T.L., J.P., Q.L., Y.S. and P.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by grants from the National Natural Science Foundation of China (Nos. 82060492) and the National College Students’ Innovative Entrepreneurial Training Plan Program (202110403003).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Buckwalter, J.; Martin, J. Osteoarthritis. *Adv. Drug Deliv. Rev.* 2006, 58, 150–167. [CrossRef] [PubMed]

2. Hunter, D.J.; March, L.; Chew, M. Osteoarthritis in 2020 and beyond: A Lancet Commission. *Lancet* 2020, 396, 1711–1712. [CrossRef]

3. Felson, D.; Lawrence, R.C.; Dieppe, P.A.; Hirsch, R.; Helmick, C.G.; Jordan, J.M.; Kington, R.S.; Lane, N.E.; Nevitt, M.C.; Zhang, Y.; et al. Osteoarthritis: New Insights. Part I: The Disease and Its Risk Factors. *Ann. Intern. Med.* 2000, 133, 635–646. [CrossRef] [PubMed]

4. Spector, T.D.; Cicuttini, F.; Baker, J.; Loughlin, J.; Hart, D. Genetic influences on osteoarthritis in women: A twin study. *BMJ* 1996, 312, 940–943. [CrossRef] [PubMed]

5. Latourte, A.; Kloppenburg, M.; Richette, P. Emerging pharmaceutical therapies for osteoarthritis. *Nat. Rev. Rheumatol.* 2020, 16, 673–688. [CrossRef]

6. Kelwick, R.; Desanlis, I.; Wheeler, G.N.; Edwards, D.R. The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. *Genome Biol.* 2015, 16, 113. [CrossRef]

7. Rienks, M.; Barallobre-Barreiro, J.; Mayr, M. The Emerging Role of the ADAMTS Family in Vascular Diseases. *Circ. Res.* 2018, 123, 1279–1281. [CrossRef]

8. Russell, D.L.; Brown, H.M.; Dunning, K.R. ADAMTS proteases in fertility. *Matrix Biol.* 2015, 44–46, 54–63. [CrossRef]

9. Cal, S.; López-Otin, C. ADAMTS proteases and cancer. *Matrix Biol.* 2015, 44–46, 77–85. [CrossRef]

10. Stanton, H.; Melrose, J.; Little, C.B.; Fosang, A.J. Proteoglycan degradation by the ADAMTS family of proteinases. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* 2011, 1812, 1616–1629. [CrossRef]

11. Clause, K.C.; Barker, T.H. Extracellular matrix signaling in morphogenesis and repair. *Curr. Opin. Biotechnol.* 2013, 24, 830–833. [CrossRef] [PubMed]

12. Kang, Z.; Zhou, Z.; Wang, Y.; Huang, H.; Du, G.; Chen, J. Bio-Based Strategies for Producing Glicosaminoglycans and Their Oligosaccharides. *Trends Biotechnol.* 2018, 36, 806–818. [CrossRef] [PubMed]

13. Verissimo, C.; Bicalho, A.A.; Soares, P.B.F.; Tantibrojn, D.; Versluis, A.; Soares, C.J. The effect of antagonist tooth contact on the biomechanical response of custom-fitted mouthguards. *Dent. Traumatol.* 2016, 33, 57–63. [CrossRef] [PubMed]

14. Pomin, V.H. Keratan sulfate: An up-to-date review. *Int. J. Biol. Macromol.* 2015, 72, 282–289. [CrossRef]

15. Knudson, C.B.; Knudson, W. Cartilage proteoglycans. *Semin. Cell Dev. Biol.* 2001, 12, 69–78. [CrossRef] [PubMed]

16. Theocharis, A.D.; Skandalis, S.S.; Gialeli, C.; Karamanos, N.K. Extracellular matrix structure. *Adv. Drug Deliv. Rev.* 2016, 97, 4–27. [CrossRef]

17. Luo, Y.; Sinkeviciute, D.; He, Y.; Karsdal, M.; Henrotin, Y.; Mobasher, A.; Onnerfjord, P.; Bay-Jensen, A. The minor collagens in articular cartilage. *Protein Cell* 2017, 8, 560–572. [CrossRef] [PubMed]

18. Peng, Z.; Sun, H.; Bunpetch, V.; Koh, Y.; Wen, Y.; Wu, D.; Ouyang, H. The regulation of cartilage extracellular matrix homeostasis in joint cartilage degeneration and regeneration. *Biomaterials* 2020, 268, 120555. [CrossRef]

19. Collins-Racie, L.A.; Flannery, C.R.; Zeng, W.; Corcoran, C.; Annis-Freeman, B.; Agostino, M.J.; Arai, M.; DiBlasio-Smith, E.; Dorner, A.J.; Georgiadiis, K.E.; et al. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. *Matrix Biol.* 2004, 23, 219–230. [CrossRef]
20. Dudhia, J. Aggrecan, aging and assembly in articular cartilage. *Cell. Mol. Life Sci.* 2005, 62, 2241–2256. [CrossRef]
21. Hayes, A.J.; Melrose, J. Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis: Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity. *Biomolecules* 2020, 10, 1244. [CrossRef] [PubMed]
22. Chandran, P.L.; Horkay, F. Aggrecan, an unusual polyelectrolyte: Review of solution behavior and physiological implications. *Acta Biomater.* 2012, 8, 3–12. [CrossRef] [PubMed]
23. Knudson, W.; Ishizuka, S.; Terabe, K.; Askew, E.B.; Knudson, C.B. The pericellular hyaluronan of articular chondrocytes. *Matrix Biol.* 2018, 78–79, 32–46. [CrossRef] [PubMed]
24. Albertson, P.; Dugonitsch, H.C.; Hartmann, B.; Li, P.; Farkas, Z.; Saller, M.M.; Claussen-Schaumann, H.; Aszodi, A. Aggrecan Hypomorphism Compromises Articular Cartilage Biomechanical Properties and Is Associated with Increased Incidence of Spontaneous Osteoarthritis. *Int. J. Mol. Sci.* 2019, 20, 1008. [CrossRef]
25. Kiani, C.; Chen, L.; Wu, Y.J.; Yee, A.J.; Yang, B.B. Structure and function of aggrecan. *Cell Res.* 2002, 12, 19–32. [CrossRef]
26. Struglics, A.; Hansson, M.; Lohmander, L. Human aggrecanase generated synovial fluid fragment levels are elevated directly after knee injuries due to proteolysis both in the inter globular and chondroitin sulfate domains. *Osteoarthr. Cartil.* 2011, 19, 1047–1057. [CrossRef]
27. Porter, S.; Clark, I.M.; Kevorikian, L.; Edwards, D.R. The ADAMTS metalloproteinases. *Biochim. J.* 2005, 386, 15–27. [CrossRef]
28. Longpré, J.; Leduc, R. Identification of prodomain determinants involved in ADAMTS-1 biosynthesis. *J. Biol. Chem.* 2004, 279, 33237–33245. [CrossRef]
29. Shindo, T.; Kurihara, H.; Kuno, K.; Yokoyama, H.; Wada, T.; Kurihara, Y.; Imai, T.; Wang, Y.; Ogata, M.; Nishimatsu, H.; et al. ADAMTS-1: A metalloproteinase-disintegrin es-sential for normal growth, fertility, and organ morphology and function. *J. Clin. Invest.* 2000, 105, 1345–1352. [CrossRef]
30. Kuno, K.; Matsushima, K. ADAMTS-1 protein anchors at the extracellular matrix through the thrombospondin type I motifs and its spacing region. *J. Biol. Chem.* 1998, 273, 13912–13917. [CrossRef]
31. Yang, C.Y.; Chanalaris, A.; Troeberg, L. ADAMTS and ADAM metalloproteinases in osteoarthritis—Looking beyond the ‘usual suspects’. *Osteoarthr. Cartil.* 2017, 25, 1000–1009. [CrossRef] [PubMed]
32. Kuno, K.; Okada, Y.; Kawashima, H.; Nakamura, H.; Miyasaka, M.; Ohno, H.; Matsushima, K. ADAMTS-1 cleaves a car-tilage proteoglycan, aggrecan. *FEBS Lett.* 2000, 478, 241–245. [CrossRef]
33. Kuno, K.; Terashima, Y.; Matsushima, K. ADAMTS-1 is an active metalloproteinase associated with the extracel-lular matrix. *J. Biol. Chem.* 1999, 274, 18821–18826. [CrossRef]
34. Arner, E.C. Aggrecanase-mediated cartilage degeneration. *Curr. Opin. Pharmacol.* 2002, 2, 322–329. [CrossRef]
35. Lin, W.; Kang, H.; Niu, Y.; Niu, J.; Fan, C.; Feng, X.; Wang, F. Cartilage degeneration is associated with activation of the PI3K/AKT signaling pathway in a growing rat experimental model of developmental trochlear dysplasia. *J. Adv. Res.* 2021, 35, 109–116. [CrossRef] [PubMed]
36. Nagase, H.; Kashihwagi, M. Aggrecanases and cartilage matrix degradation. *Arthritis Res. Ther.* 2003, 5, 94–103. [CrossRef]
37. Naito, S.; Shiomi, T.; Okada, A.; Kimura, T.; Chijiwa, M.; Fujita, Y.; Yatabe, T.; Komiyama, R.; Enomoto, H.; Fujikawa, K.; et al. Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. *Pathol. Int.* 2007, 57, 703–711. [CrossRef]
38. Szentléleyek, E.; Szegeczki, V.; Karanyicz, E.; Hajdú, T.; Tamás, A.; Tóth, G.; Zakány, R.; Reglodi, D.; Juhasz, T. Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) Reduces Oxidative and Mechanical Stress-Evoked Matrix Degradation in Chondrifying Cell Cultures. *Int. J. Mol. Sci.* 2019, 20, 168. [CrossRef]
39. Echtermeyer, E.; Bertrand, J.; Dreier, R.; Meinecke, I.; Neugebauer, K.M.; Fuerst, M.; Lee, Y.J.; Song, Y.W.; Herzog, C.; Theilmeier, G.; et al. Syndecan-4 regulates ADAMTS-5 activation and cartilage breakdown in osteoarthritis. *Nat. Med.* 2009, 15, 1072–1076. [CrossRef] [PubMed]
40. Cilek, M.Z.; de Vega, S.; Shiozawa, J.; Yoshinaga, C.; Miyamae, Y.; Chijiwa, M.; Mochizuki, S.; Ito, M.; Kaneko, H.; Kaneko, K.; et al. Synergistic upregulation of ADAMTS4 (aggrecanase-1) by cytokines and its suppression in knee osteoarthritic synovial fibroblasts. *Lab. Invest.* 2021, 102, 1. [CrossRef]
41. Dunn, J.R.; Panuttsopulos, D.; Shaw, M.W.; Heighway, J.; Dormer, R.; Salmo, E.N.; Watson, S.G.; Field, J.K.; Liloglou, T. MTH2 silencing and promoter hypermethylation in NSCLC. *Br. J. Cancer* 2004, 91, 1149–1154. [CrossRef] [PubMed]
42. Dunn, J.R.; Reed, J.E.; du Plessis, D.G.; Shaw, E.J.; Reeves, P.; Gee, A.L.; Warnke, P.; Walker, C. Expression of ADAMTS-8, a secreted protease with angiogenic properties, is downregulated in brain tumours. *Br. J. Cancer* 2006, 94, 1186–1193. [CrossRef] [PubMed]
43. Ayanoglu, T.; Atalar, H.; Esen, E.; Ataoglu, M.B.; Turanli, S.; Demircan, K. The role of ADAMTS genes in the end stage of hip osteoarthritis. *Acta Orthop. Traumatol. Turc.* 2019, 53, 140–144. [CrossRef] [PubMed]
44. Shen, Q.; Polom, K.; Williams, C.; de Oliveira, F.M.S.; Guergova-Kuras, M.; Lisacek, F.; Karlsson, N.G.; Roviello, F.; Kamali-Moghaddam, M. A targeted proteomics approach reveals a serum protein signature as diagnostic biomarker for resectable gastric cancer. *EBioMedicine* 2019, 44, 322–333. [CrossRef]
45. Kelwick, R.; Wagstaff, L.; Decock, J.; Roghi, C.; Cooley, L.S.; Robinson, S.D.; Arnold, H.; Gavrilović, J.; Jaworski, D.M.; Yamamoto, K.; et al. Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15. *Int. J. Cancer* 2014, 136, E14–E26. [CrossRef]
46. Binder, M.J.; McCoombe, S.; Williams, E.D.; McCulloch, D.R.; Ward, A.C. ADAMTS-15 Has a Tumor Suppressor Role in Prostate Cancer. *Biomolecules* 2020, 10, 682. [CrossRef]

47. Molokwu, C.N.; Adeniji, O.O.; Chandrasekharan, S.; Hamdy, F.C.; Buttle, D.J. Androgen Regulates ADAMTS15 Gene Expression in Prostate Cancer Cells. *Cancer Investig.* 2010, 28, 698–710. [CrossRef]

48. Bekhouche, M.; Colige, A. The procollagen N-proteinases ADAMTS2, 3 and 14 in pathophysiology. *Matrix Biol.* 2015, 44–46, 46–53. [CrossRef]

49. Stefanovic, B. RNA-protein interactions governing expression of the most abundant protein in human body, type I collagen. *Wiley Interdiscip. Rev.* 2013, 4, 535–545. [CrossRef]

50. Shi, R.; Zhang, Z.; Zhu, A.; Xiong, X.; Zhang, J.; Xu, J.; Sy, M.; Li, C. Targeting type I collagen for cancer treatment. *Int. J. Cancer* 2022. [CrossRef]

51. Gistelinck, C.; Kwon, R.Y.; Malfait, F.; Symoens, S.; Harris, M.P.; Henke, K.; Hawkins, M.B.; Fisher, S.; Sips, P.; Guillemin, B.; et al. Zebrafish type I collagen mutants faithfully recapitulate human type I collagenopathies. *Proc. Natl. Acad. Sci. USA* 2018, 115, E8037–E8046. [CrossRef] [PubMed]

52. Holland, A.P.; Pidoux, I.; Reiner, A.; Rorabeck, C.; Bourne, R.; Poole, A.R. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. *J. Clin. Invest.* 1995, 96, 2859–2869. [CrossRef][PubMed]

53. Aszodi, A.; Hunziker, E.B.; Olsen, B.R.; Fassler, R. The role of collagen II and cartilage fibril-associated molecules in skeletal development. *Osteoarthr. Cartil.* 2001, 9, S150–S159.

54. Wang, W.-M.; Lee, S.; Steiglitz, B.M.; Scott, I.C.; Lebares, C.C.; Allen, M.L.; Brenner, M.C.; Takahara, K.; Greenspan, D.S. Cleavage of type I procollagen by C- and N-proteinases is more rapid if the substrate is aggregated with dextran sulfate or polyethylene glycol. *Anal. Biochem.* 1994, 223, 173–180. [CrossRef]

55. Czarny-Ratajczak, M.; Lohiniva, J.; Rogala, P.; Kozlowski, K.; Perälä, M.; Carter, L.; Spector, T.D.; Kolodziej, L.; Seppänen, U.; Glazar, R.; et al. A Mutation in COL9A1 Causes Multiple Epiphyseal Dysplasia: Further Evidence for Locus Heterogeneity. *Am. J. Hum. Genet.* 2001, 69, 969–980. [CrossRef][PubMed]

56. Prockop, D.J.; Sironi, A.L.; Li, S.W. Procollagen N-proteinase and procollagen C-proteinase. Two unusual metallo-proteinases that are essential for procollagen processing probably have important roles in development and cell signaling. *Matrix Biol.* 1998, 16, 399–408. [CrossRef]

57. Seddon, J.; Kasprzowicz, V.; Walker, N.; Yuen, H.M.; Sunpath, H.; Tezera, L.; Meintjes, G.; Wilkinson, R.; Bishai, W.R.; Friedland, J.S.; et al. Procollagen III N-Terminal Propeptide and Desmosine are Released by Matrix Destruction in Pulmonary Tuberculosis. *J. Infect. Dis.* 2013, 208, 1571–1579. [CrossRef]

58. Hojima, Y.; Behta, B.; Romanic, A.M.; Prockop, D.J. Cleavage of type I procollagen by C- and N-proteinases is more rapid if the substrate is aggregated with dextran sulfate or polyethylene glycol. *Anal. Biochem.* 1994, 223, 173–180. [CrossRef]

59. Dubail, J.; Kesteloot, F.; Deroanne, C.; Motte, P.; Lambert, V.; Rakic, J.-M.; Lapièrre, C.; Nusgens, B.; Colige, A. ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity. *Cell. Mol. Life Sci.* 2010, 67, 4213–4232. [CrossRef]

60. Malfait, F. Vascular aspects of the Ehlers-Danlos Syndromes. *Matrix Biol.* 2018, 71–72, 380–395. [CrossRef]

61. Jeltsch, M.; Jha, S.K.; Tvorogov, D.; Anisimov, A.; Leppänen, V.-M.; Holopainen, T.; Kivelä, R.; Ortega, S.; Kärpanen, T.; Alitalo, K. Metalloproteinase ADAMTS-3 Inactivates Reelin. *J. Neurosci.* 2014, 39, 34397–34408. [CrossRef] [PubMed]

62. Ma, S.; Ouyang, C.; Ren, S. Relationship between ADAMTS14/rs4747096 gene polymorphism and knee osteoarthritis in Chinese population. *Biosci. Rep.* 2018, 38, BSR20181413. [CrossRef][PubMed]

63. Maile, M.;-video, I.; Reiner, A.; Rorabeck, C.; Bourne, R.; Poole, A.R. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. *J. Clin. Invest.* 1995, 96, 2859–2869. [CrossRef][PubMed]

64. Alper, M.; Kockar, F. IL-6 upregulates a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS-2) in human osteosarcoma cells mediated by JNK pathway. *Mol. Cell. Biochem.* 2014, 393, 165–175. [CrossRef]

65. Wang, W.-M.; Lee, S.; Steiglitz, B.M.; Scott, I.C.; Lebares, C.C.; Allen, M.L.; Brenner, M.C.; Takahara, K.; Greenspan, D.S. Transforming Growth Factor-β Induces Secretion of Activated ADAMTS-2. A procollagen III N-proteinase. *J. Biol. Chem.* 2003, 278, 19549–19557. [CrossRef]

66. Lesiak, M.; Augusciak-Duma, A.; Szydló, A.; Pruszczyńska, K.; Sironi, A.L. Specific inhibition of procollagen C-endopeptidase activity by synthetic peptide with conservative sequence found in chordin. *Acta Biochim. Pol.* 2008, 55, 297–305. [CrossRef]

67. Fernandez, R.J.; Hirohata, S.; Engle, J.M.; Colige, A.; Cohn, D.H.; Eyre, D.R.; Apte, S.S. Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. *J. Biol. Chem.* 2001, 276, 31502–31509. [CrossRef]

68. Colige, A.; Ruggiero, F.; Vandenbergh, I.; Dubail, J.; Kesteloot, F.; Van Beeumen, J.; Beschin, A.; Brys, L.; Lapièrre, C., M.; Nusgens, B. Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the ami-nopropoepide of fibrillar procollagens types I-III and V. *J. Biol. Chem.* 2005, 280, 34397–34408. [CrossRef]

69. Li, Q.; Wang, C.; Wang, Y.; Sun, L.; Liu, Z.; Wang, L.; Song, T.; Yao, Y.; Liu, Q.; Tu, K. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways. *J. Exp. Clin. Cancer Res.* 2018, 37, 231. [CrossRef]

70. Metharam, P.; Berndt, M.C. COMP: An endogenous thrombin inhibitor. *Blood* 2015, 126, 831–832. [CrossRef]
71. Hecht, J.T.; Hayes, E.; Haynes, R.; Cole, W.G. COMP mutations, chondrocyte function and cartilage matrix. Matrix Biol. 2005, 23, 525–533. [CrossRef] [PubMed]

72. Chen, J.; Zhang, W.; He, J.; Zhang, C.; Cao, Y.; Liu, X. A novel mutation in exon 11 of COMP gene in a Chinese family with pseudoachondroplasia. Genes Dis. 2018, 6, 47–55. [CrossRef] [PubMed]

73. Maly, K.; Sastre, E.A.; Farrell, E.; Meurer, A.; Zaucke, F. COMP and TSP-4: Functional Roles in Articular Cartilage and Relevance in Osteoarthritis. Int. J. Mol. Sci. 2021, 22, 2242. [CrossRef] [PubMed]

74. Liu, C.-J.; Kong, W.; Xu, K.; Luan, Y.; Halov, K.; Sehgal, B.; Yu, S.; Howell, R.D.; Di Cesare, P.E. ADAMTS-12 associates with and degrades cartilage oligomeric matrix protein. J. Biol. Chem. 2006, 281, 15800–15808. [CrossRef]

75. Zhang, Y.; Wei, F.; Liu, C.-J. Overexpression of ADAMTS-7 leads to accelerated initiation and progression of collagen-induced arthritis in mice. Mol. Cell. Biochem. 2015, 404, 171–179. [CrossRef]

76. Buckley, J. Osteoarthritis: Positive feedback between ADAMTS-7 and TNF in OA. Nat. Rev. Rheumatol. 2013, 9, 566. [CrossRef]

77. Lai, Y.; Bai, X.; Zhao, Y.; Tian, Q.; Liu, B.; Lin, E.A.; Chen, Y.; Lee, B.; Appleton, C.T.; Beier, F.; et al. ADAMTS-7 forms a positive feedback loop with TNF-α in the pathogenesis of osteoarthritis. Ann. Rheum. Dis. 2013, 73, 1575–1584. [CrossRef]

78. Hesselson, D.; Newman, C.; Kim, K.W.; Kimble, J. GON-1 and fibulin have antagonistic roles in control of organ shape. Curr. Biol. 2004, 14, 2005–2010. [CrossRef]

79. Ismat, A.; Cheshire, A.M.; Andrew, D.J. The secreted ADAMTS-A metalloprotease is required for collective cell migration. Development 2013, 140, 1981–1993. [CrossRef]

80. Yakasli, K.O.; Hatipoglu, O.F.; Yakasli, E.; Yildirim, K.; Kaya, E.; Ozsahin, M.; Uslu, M.; Gunduz, E. Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-kB signaling pathways in human chondrocytes. Cell Biol. Int. 2014, 38, 104–112. [CrossRef]

81. Rogerson, F.M.; Last, K.; Golub, S.B.; Gauci, S.J.; Stanton, H.; Bell, K.M.; Fosang, A.J. ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5. Int. J. Mol. Sci. 2019, 20, 573. [CrossRef]

82. Nowak, A.A.; O’Brien, H.E.R.; Henne, P.; Doerr, A.; Vanhoorelbeke, K.; Laffan, M.; McKinnon, T.A. ADAMTS-13 glycans and conformation-dependent activity. J. Thromb. Haemost. 2017, 15, 1155–1166. [CrossRef] [PubMed]

83. Adkins, L.E.; Baicu, C.F.; Zile, M.R.; Lindsey, M.L.; Bradshaw, A.D. Increased ADAMTS1 mediates SPARC-metalloproteinase with Thrombospondin Motifs-19 Levels in Different Fertility Situations: Could It be a Serum Marker of Ovarian Function and Oocyte Pool? Gynecol. Obstet. Invest. 2018, 84, 6–11. [CrossRef] [PubMed]

84. Liu, L.; Yang, Z.; Ni, W.; Xuan, Y. ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma. Exp. Mol. Pathol. 2018, 104, 134–139. [CrossRef] [PubMed]

85. Mularczyk, E.J.; Singh, M.; Godwin, A.R.F.; Galli, F.; Humphreys, N.; Adamson, A.D.; Mironov, A.; Cain, S.A.; Sengle, G.; Boot-Handford, R.; et al. ADAMTS10-mediated tissue disruption in the Weil–Marchesani syndrome. Hum. Mol. Genet. 2018, 27, 3675–3687. [CrossRef] [PubMed]

86. Surridge, A.K.; Rodgers, U.R.; Swingler, T.E.; Davidson, R.K.; Kevorkian, L.; Horton, R.; Waters, J.G.; Goldring, M.B.; Parker, A.E.; Clark, I.M. Characterization and regulation of ADAMTS-16. Matrix Biol. 2009, 28, 416–424. [CrossRef]

87. Ersoy, E.; Özlü, S.; Oztas, E.; Ersoy, A.; Ergin, M.; Tokmak, A.; Yilmaz, N. Comparison of Serum A Disintegrin and Metalloproteinase with Thrombospondin Motifs-19 Levels in Different Fertility Situations: Could It be a Serum Marker of Ovarian Function and Oocyte Pool? Gynecol. Obstet. Investig. 2018, 84, 6–11. [CrossRef] [PubMed]

88. Toba, H.; de Castro Brás, L.E.; Baicu, C.F.; Zile, M.R.; Lindsey, M.L.; Bradshaw, A.D. Increased ADAMTS1 mediates SPARC-dependent collagen deposition in the aging myocardium. Am. J. Physiol. Endocrinol. Metab. 2016, 310, E1027–E1035. [CrossRef]

89. Golbasi, F.; Erdemir, A.; Kisa, U. Comparison of ADAMTS Levels in Pulp Tissue Samples of Healthy and Symptomatic Irreversible Pulpitis Teeth. J. Endod. 2021, 48, 496–501. [CrossRef]

90. Rehn, A.P.; Birch, M.A.; Karlström, E.; Wendel, M.; Lind, T. ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing. Bone 2007, 41, 231–238. [CrossRef]

91. Miles, R.R.; Sluka, J.P.; Halladay, D.L.; Santerre, R.F.; Hale, L.V.; Bloem, L.; Thirunavukkarasu, K.; Galvin, R.J.; Hock, J.M.; Onyia, J.E. ADAMTS-1: A cellular disintegrin and metalloproteinase with thrombospondin motifs is a target for parathyroid hor-mone in bone. Endocrinology 2000, 141, 4533–4542. [CrossRef] [PubMed]

92. Dong, C.; Li, H.-J.; Chang, S.; Liao, H.-J.; Zhang, Z.-P.; Huang, P.; Tang, H.-H. A Disintegrin and Metalloproteinase with Thrombospondin Motif 2 May Contribute to Cirrhosis in Humans through the Transforming Growth Factor-β/SMAD Pathway. Gut Liver 2013, 7, 213–220. [CrossRef] [PubMed]

93. Van Damme, T.; Colige, A.; Sny, D.; Giunta, C.; Lindert, U.; Rohrbach, M.; Aryani, O.; Alayay, Y.; Simsek-Kiper, P.; Kroes, H.Y.; et al. Expanding the clinical and mutational spectrum of the Ehlers–Danlos syndrome, dermatosparaxis type. Genet. Med. 2016, 18, 882–891. [CrossRef] [PubMed]

94. Leduc, C.; Dupont, L.; Joannes, L.; Monseur, C.; Bavin, D.; Mazzucchelli, G.; Deroanne, C.; Colige, A.; Bekhouche, M. In vivo N-Terminomics Highlights Novel Functions of ADAMTS2 and ADAMTS14 in Skin Collagen Matrix Building. Front. Mol. Biosci. 2021, 8, 643178. [CrossRef]

95. Akyol, S.; Çomertoglu, I.; Fırat, R.; Cakmak, O.; Yukselten, Y.; Erden, G.; Ugurcu, V.; Demircan, K. Effect of insulin on the mRNA expression of procollagen N-proteinases in chondrosarcoma OUMS-27 cells. Oncol. Lett. 2015, 10, 1091–1096. [CrossRef] [PubMed]
Biomolecules 2022, 12, 959

96. Collige, A.; Li, S.-W.; Sieron, A.L.; Nusgens, B.V.; Prockop, D.J.; Lapière, C.M. cDNA cloning and expression of bovine procollagen I N-proteinase: A new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc. Natl. Acad. Sci. USA 1997, 94, 2374–2379. [CrossRef] [PubMed]

97. Jiang, C.; Zhou, Y.; Huang, Y.; Wang, Y.; Wang, W.; Kuai, X. Overexpression of ADAMTS-2 in tumor cells and stroma is predictive of poor clinical prognosis in gastric cancer. Hum. Pathol. 2018, 84, 44–51. [CrossRef]

98. Janssen, L.; Dupont, L.; Bekhouche, M.; Noel, A.; Leduc, C.; Voz, M.; Peers, B.; Cataldo, D.; Apte, S.S.; Dubail, J.; et al. ADAMTS3 activity is mandatory for embryonic lymphangiogenesis and regulates placental angiogenesis. Angiogenesis 2015, 19, 53–65. [CrossRef]

99. Jha, S.K.; Rauniyar, K.; Karpanen, T.; Leppänen, V.-M.; Brouillard, P.; Vilkka, M.; Alitalo, K.; Jeltsch, M. Efficient activation of the fibrinolytic enzyme ADAMTS-1, and METH-2 are members of a new family of zinc metalloproteinases. J. Biol. Chem. 1999, 274, 23443–23450. [CrossRef]

100. Boerboom, D.; Lafond, J.-F.; Zheng, X.; Lapointe, E.; Mittaz, L.; Boyer, A.; Pritchard, M.A.; DeMayo, F.J.; Mort, J.S.; Drolet, R.; et al. Partially redundant functions of ADAMts1 and ADAMts4 in the perinatal development of the renal medulla. Dev. Dyn. 2011, 240, 1806–1814. [CrossRef]

101. Dubail, J.; Apte, S.S. Insights on ADAMTS proteases and ADAMTS-like proteins from mammalian genetics. Matrix Biol. 2015, 44–46, 24–37. [CrossRef] [PubMed]

102. Lemarchant, S.; Pomeschik, Y.; Kidin, I.; Kärkkäinen, V.; Valonen, P.; Lehtonen, S.; Goldsteins, G.; Malm, T.; Kanninen, K.; Koistinaho, J. ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis. Mol. Neurodegener. 2016, 11, 10. [CrossRef] [PubMed]

103. Delarue, Q.; Mayeur, A.; Chalfouh, C.; Honoré, A.; Duclos, C.; Di Giovanni, M.; Li, X.; Salaun, M.; Dampierre, J.; Vaudry, D.; et al. Critical Role of ADAMTS-4 in the Development of Sporadic Aortic Aneurysm and Dissection in Mice. Sci. Rep. 2017, 7, 12351. [CrossRef]

104. Novak, R.; Hrkac, S.; Salai, G.; Bilandzic, J.; Mitar, L.; Grgurevic, L. The Role of ADAMTS-4 in Atherosclerosis and Vessel Wall Abnormalities. J. Vasc. Res. 2022, 59, 69–77. [CrossRef]

105. Novak, R.; Hrkac, S.; Salai, G.; Bilandzic, J.; Mitar, L.; Grgurevic, L. ADAMTS-4, a Metalloproteinase That Directly Binds to and Degradates Cartilage Oligomeric Matrix Protein. Mol. Med. Rep. 2018, 17, 507–516. [CrossRef]

106. Linnet, J.; Peterson, E.; Doudet, D.J.; Gjedde, A.; Möller, A. Dopamine release in ventral striatum of pathological gamblers losing money. Acta Psychiatr. Scand. 2010, 122, 326–333. [CrossRef]

107. Ahmad, D.; Sato, T.S.; Kohilan, A.; Tayeh, M.; Chen, S.; Leal, S.; Al-Salem, M.; El-Shanti, H. A Homozygous Mutation in ADAMTS14 Causes Autosomal-Recessive Isolated Ectopia Lentis. Am. J. Hum. Genet. 2009, 84, 274–278. [CrossRef]

108. Abbassade, I.; Liu, R.-Q.; Yang, F.; Rosenfeld, S.A.; Ross, O.H.; Link, J.R.; Ellis, D.M.; Tortorella, M.D.; Pratta, M.A.; Hollis, J.M.; et al. Cloning and Characterization of ADAMTS11, an Aggrecanase from the ADAMTS Family. J. Biol. Chem. 1999, 274, 23443–23450. [CrossRef]

109. Hurksainen, T.L.; Hirohata, S.; Seldin, M.F.; Apte, S. ADAM-T5, ADAM-T6, and ADAM-T57, Novel Members of a New Family of Zinc Metalloproteinases. General features and genomic distribution of the ADAM-TS family. J. Biol. Chem. 2010, 285, 12555–12563. [CrossRef]

110. Hanby, H. Biochemistry and Physiological Functions of ADAMTS7 Metalloproteinase. Adv. Biochem. 2013, 1, 43. [CrossRef]

111. Kessler, T.; Zhang, L.; Liu, Z.; Yin, X.; Huang, Y.; Wang, Y.; Fu, Y.; Mayr, M.; de Angelis, M.H.; Xu, Q.; et al. ADAMTS-7 Inhibits Re-endothelialization of Injured Arteries and Promotes Vascular Remodeling Through Cleavage of Thrombospondin-1. Circulation 2015, 131, 1191–1201. [CrossRef] [PubMed]

112. Zhang, L.; Yu, F.; Wang, L.; Zheng, J.; Du, Y.; Huang, Y.; Liu, B.; Wang, X.; Kong, W. ADAMTS-7 promotes vascular smooth muscle cells proliferation in vitro and in vivo. Sci. China Life Sci. 2015, 58, 674–681. [CrossRef] [PubMed]

113. Hosseini, D.K.; Ateikia, S.; Hosseini, H.K.; Han, B.; Sun, H. Association of polymorphisms in ADAMTS-7 gene with the susceptibility to coronary artery disease—A systematic review and meta-analysis. Aging 2020, 12, 20915–20923. [CrossRef]

114. Vázquez, F.; Hastings, G.; Ortega, M.-A.; Lane, T.P.; Okemus, S.; Lombardo, M.; Iruela-Arispe, M.L. METH-1, a Human Ortholog of ADAMTS-1, and METH-2 Are Members of a New Family of Proteins with Angio-inhibitory Activity. J. Biol. Chem. 1999, 274, 23349–23357. [CrossRef]

115. Desanlis, I.; Felstead, H.L.; Edwards, D.R.; Wheeler, G.N. ADAMTS9, a member of the ADAMTS family, in Xenopus development. Gene Expr. Patterns 2018, 29, 72–81. [CrossRef]
120. Uhlig, T.; Heumann, M.; Zweck, J. Development of a specimen holder for in situ generation of pure in-plane magnetic fields in a transmission electron microscope. *Ultramicroscopy* 2002, 94, 193–196. [CrossRef]

121. Koo, B-H.; Coe, D.M.; Dixon, L.J.; Somerville, R.P.; Nelson, C.M.; Wang, L.W.; Young, M.E.; Lindner, D.J.; Apte, S.S. ADAMTS9 Is a Cell-Autonomously Acting, Anti-Angiogenic Metalloprotease Expressed by Microvascular Endothelial Cells. *Am. J. Pathol. 2010*, 176, 1494–1504. [CrossRef] [PubMed]

122. Sun, Y.; Sun, X.; Liu, Z.; Wang, X.; Li, Y. MiR-338-5p suppresses rheumatoid arthritis synovial fibroblast proliferation and invasion by targeting ADAMTS-9. *Clin. Exp. Rheumatol.* 2018, 36, 195–202. [PubMed]

123. Somerville, R.P.; Jungers, K.A.; Apte, S.S. Discovery and Characterization of a Novel, Widely Expressed Metalloprotease, ADAMTS10, and Its Proteolytic Activation. *J. Biol. Chem. 2004*, 279, 51208–51217. [CrossRef] [PubMed]

124. Kutz, W.E.; Wang, L.W.; Bader, H.L.; Majors, A.K.; Iwata, K.; Traboulsi, E.I.; Sakai, L.Y.; Keene, D.R.; Apte, S.S. ADAMTS10 Protein Interacts with Fibrillin-1 and Promotes Its Deposition in Extracellular Matrix of Cultured Fibroblasts. *J. Biol. Chem.* 2011, 286, 17156–17167. [CrossRef]

125. Dagoneau, N.; Benoist, C.; Huber, C.; Faivre, L.; Mégarbané, A.; Alswaid, A.; Dollfus, H.; Alembik, Y.; Munnich, A.; Legeai-Mallet, L.; et al. ADAMTS10 Mutations in Autosomal Recessive Weill-Marchesani Syndrome. *Am. J. Hum. Genet.* 2004, 75, 801–806. [CrossRef]

126. Paulissen, G.; El Hour, M.; Rocks, N.; Guéde, M.M.; Bureau, F.; Foidart, J.-M.; López-Otin, C.; Noel, A.; Cataldo, D. Control of Allergen-Induced Inflammation and Hyperresponsiveness by the Metalloprotease ADAMTS12. *J. Immunol.* 2012, 189, 4135–4143, Erratum in *J. Immunol.* 2017, 207, 2388–2389. [CrossRef]

127. Mohamedi, Y.; Fontani, T.; Cal, S.; Cobo, T.; Obaya, J. ADAMTS-12: Functions and Challenges for a Complex Metalloprotease. *Front. Mol. Biosci.* 2021, 8, 686763. [CrossRef]

128. Mead, T.J.; Apte, S.S. ADAMTS proteins in human diseases. *Matrix Biol.* 2018, 71–72, 225–239. [CrossRef]

129. Zheng, X.L. ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura. *Annu. Rev. Med.* 2015, 66, 211–225. [CrossRef]

130. Moske, J.L. Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. *Semin. Hematol.* 2004, 41, 4–14. [CrossRef] [PubMed]

131. Levy, G.G.; Nichols, W.C.; Lian, E.C.; Foroud, T.; McClintick, J.N.; McGee, B.M.; Yang, A.Y.; Siemieniak, D.R.; Stark, K.R.; Gruppo, R.; et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature 2001*, 413, 488–494. [CrossRef] [PubMed]

132. Cal, S.; Obaya, A.J.; Llamazares, M.; Garabaya, C.; Quesada, V.; López-Otin, C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. *Gene 2002*, 283, 49–62. [CrossRef]

133. Goerttsches, R.; Comabella, M.; Navarro, A.; Perkal, H.; Montalban, X. Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. *J. Neuroimmunol.* 2005, 164, 140–147. [CrossRef]

134. Poopnet, T.; Hanswek, S.; Tamamchote, R.; Kanitnate, S. ADAMTS14 gene polymorphism associated with knee osteoarthritis in Thai women. *Genet. Mol. Res.* 2013, 12, 5301–5309. [CrossRef]

135. Rodriguez-Lopez, J.; Pombo-Suarez, M.; Llamazares, M.; Cal, S.; Quesada, V.; Lóguez-Otí, C.; et al. Identification and characterization of ADAMTS-20 defines a novel subfamily of metalloproteinases-disintegrins with multiple thrombospondin-1 repeats and a unique GON domain. *J. Biol. Chem.* 2013, 288, 37267–37276. [CrossRef]

136. Morales, J.; Al-Sharif, L.; Khalil, D.S.; Shinwari, J.M.; Bavi, P.; Al-Mahrouri, R.A.; Al-Rajhi, A.; Alkuraya, F.S.; Meyer, B.F.; Al-Tassan, N. Homozygous Mutations in ADAMTS10 and ADAMTS17 Cause Lenticular Myopia, Ectopia Lentis, Glaucoma, Spherophakia, and Short Stature. *Clin. Exp. Rheumatol.* 2010, 28, 461–473. [CrossRef]

137. Dancevic, C.M.; Fraser, F.W.; Smith, A.D.; Stupka, N.; Ward, A.C.; McCulloch, D.R. Biosynthesis and Expression of a Disintegrin-like and Metalloproteinase Domain with Thrombospondin-1 Repeats-15: A novel versican-cleaving proteoglycanase. *J. Biol. Chem.* 2013, 288, 1495–1505. [CrossRef]

138. Aldahmesh, M.A.; Alshammari, M.J.; Khan, A.O.; Mohamed, J.Y.; Alhabib, F.A.; Alkuraya, F.S. The Syndrome of Microcornea, Myopic Chorioretinal Atrophy, and Telecanthus (MMCAT) Is Caused by Mutations in ADAMTS18. *Hum. Mutat.* 2013, 34, 801–806. [CrossRef] [PubMed]

139. Zhu, R.; Cheng, M.; Lu, T.; Yang, N.; Ye, S.; Pan, Y.-H.; Hong, T.; Dang, S.; Zhang, W. A Disintegrin and Metalloproteinase with Thrombospondin Motifs 18 Deficiency Leads to Visceral Adiposity and Associated Metabolic Syndrome in Mice. *Am. J. Pathol.* 2009, 175, 312–321. [CrossRef]

140. Somerville, R.P.T.; Longpre, J.-M.; Jungers, K.A.; Engle, J.M.; Ross, M.; Evanko, S.; Wight, T.N.; Leduc, R.; Apte, S.S. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. *J. Biol. Chem.* 2003, 278, 9503–9513. [CrossRef] [PubMed]
170. Robinson, W.H.; Lepus, C.M.; Wang, Q.; Raghu, H.; Mao, R.; Lindstrom, T.M.; Sokolove, J. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat. Rev. Rheumatol. 2016, 12, 580–592. [CrossRef] [PubMed]

171. Sokolove, J.; Lepus, C.M. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther. Adv. Musculoskeletal. Dis. 2013, 5, 77–94. [CrossRef] [PubMed]

172. Houard, X.; Goldring, M.R.; Berenbaum, F. Homeostatic Mechanisms in Articular Cartilage and Role of Inflammation in Osteoarthritis. Curr. Rheumatol. Rep. 2013, 15, 375. [CrossRef] [PubMed]

173. Felson, D.T.; Anderson, J.J.; Naimark, A.; Walker, A.M.; Meenan, R.F. Obesity and knee osteoarthritis. The Framing-ham Study. Ann. Intern. Med. 1988, 109, 18–24. [CrossRef]

174. Berenbaum, F.; Eymard, F.; Houard, X. Osteoarthritis, inflammation and obesity. Curr. Opin. Rheumatol. 2013, 25, 114–118. [CrossRef]

175. Wang, T.; He, C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018, 44, 38–50. [CrossRef]

176. Chuandong, W.; Zhao, X.; Wang, C.; Geng, Y.; Zhao, J.; Xu, J.; Zuo, B.; Zhao, C.; Wang, C.; Zhang, X. MicroRNA-145 attenuates apoptosis and extracellular matrix degradation after injurious compression of mature articular cartilage. Osteoarthr. Cartil. 2020, 28, 658–668. [CrossRef] [PubMed]

177. Luan, Y.; Kong, L.; Howell, D.; Ilalov, K.; Fajardo, M.; Bai, X.-H.; Di Cesare, P.; Goldring, M.; Abramson, S.; Liu, C.-J. Inhibition of TNF-α-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4. Cell Death Dis. 2017, 8, e3140. [CrossRef]

178. Wang, L.; Yang, M.; Zhang, C.; Huang, F. The protective effects of dehydrocostus lactone against TNF-α-induced degeneration of extracellular matrix (ECM) in SW1353 cells. Aging 2020, 12, 17137–17149. [CrossRef]

179. Guo, X.; Wang, L.; Xu, M.; Bai, J.; Shen, J.; Yu, B.; Liu, Y.; Sun, H.; Hao, Y.; Geng, D. ShiKemic acid prevents cartilage matrix destruction in human chondrocytes. Int. Immunopharmacol. 2018, 63, 155–160. [CrossRef]

180. Dinarello, C.A. Interleukin-1. Cytokine Growth Factor Rev. 1997, 8, 253–265. [CrossRef]

181. Di Paolo, N.C.; Shyakhmetov, D.M. Interleukin 1α and the inflammatory process. Nat. Immunol. 2016, 17, 906–913. [CrossRef] [PubMed]

182. Ohashi, H.; Nishida, K.; Yoshida, A.; Nasu, Y.; Nakahara, R.; Matsumoto, Y.; Takeshita, A.; Kaneda, D.; Saeki, M.; Ozaki, T. Adipose-Derived Extract Suppresses IL-1β-Induced Inflammatory Signaling Pathways in Human Chondrocytes and Ameliorates the Cartilage Destruction of Experimental Osteoarthritis in Rats. Int. J. Mol. Sci. 2021, 22, 9781. [CrossRef]

183. Mladenovic, Z.; Sauder, A.-S.; Berenbaum, F.; Jacques, C. Potential Role of Hyaluronic Acid on Bone in Osteoarthritis. Aging 2014, 41, 945–954. [CrossRef] [PubMed]

184. Ren, C.; Jin, J.; Hu, W.; Chen, Q.; Yang, J.; Wu, Y.; Zhou, Y.; Sun, L.; Gao, W.; Zhang, X.; et al. Betulin Alleviates the Inflammatory Response in Mouse Chondrocytes and Ameliorates Osteoarthritis via AKT/Nrf2/HO-1/NF-κB Axis. Front. Pharmacol. 2021, 12, 754038. [CrossRef] [PubMed]

185. Luan, Y.; Kong, L.; Howell, D.; Ilalov, K.; Fajardo, M.; Bai, X.-H.; Di Cesare, P.; Goldring, M.; Abramson, S.; Liu, C.-J. Inhibition of ADAMTS-5 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthr. Cartil. 2008, 16, 1413–1420. [CrossRef]

186. Sharma, N.; Drobinski, P.; Kayed, A.; Chen, Z.; Kjellgaard-Petersen, C.; Gantzcl, T.; Karsdal, M.; Michaelis, M.; Ladel, C.; Bay-Jensen, A.; et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthr. Cartil. 2020, 28, 658–668. [CrossRef] [PubMed]

187. Ridker, P.M.; Rane, M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ. Res. 2021, 128, 1728–1746. [CrossRef]

188. Latourte, A.; Cherifi, C.; Maillet, J.; Ea, H.K.; Bouaziz, W.; Funck-Brentano, T.; Cohen-Solal, M.; Hay, E.; Richette, P. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann. Rheum. Dis. 2016, 76, 748–755. [CrossRef]

189. Moore, K.W.; de Waal Malefyt, R.; Coffman, R.L.; O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Nat. Rev. Rheumatol. 2016, 12, 580–592. [CrossRef] [PubMed]

190. Behrendt, P.M.; Preusse-Prange, A.; Klütter, T.; Haake, M.; Roluaffs, B.; Grodzinsky, A.J.; Lippross, S.; Kurz, B. IL-10 reduces apoptosis and extracellular matrix degradation after injurious compression of mature articular cartilage. Osteoarthr. Cartil. 2016, 24, 1981–1988. [CrossRef] [PubMed]

191. Appleton, C.T.G.; Usmani, S.E.; Pest, M.A.; Pitelka, V.; Mort, J.S.; Beier, F. Reduction in Disease Progression by Inhibition of Transforming Growth Factor-α-CCL2 Signaling in Experimental Posttraumatic Osteoarthritis. Arthritis Rheumatol. 2015, 67, 2691–2701. [CrossRef] [PubMed]

192. Uchida, K.; Takano, S.; Matsumoto, T.; Nagura, N.; Inoue, G.; Itakura, M.; Miyagi, M.; Aikawa, J.; Iwase, D.; Minatani, A.; et al. Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-α stimulation of synovial cells: An in vitro study. BMC Musculoskelet. Disord. 2017, 18, 283. [CrossRef] [PubMed]

193. Mouhitarat, N.; Lesur, C.; Thomas, M.; Rolland-Valognes, G.; Pastoureau, P.; Anract, P.; De Ceuninck, F.; Sabatini, M. Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthr. Cartil. 2004, 12, 296–305. [CrossRef]
Biomolecules 2022, 12, 959

194. Deng, Z.; Chen, F.; Liu, Y.; Wang, J.; Lu, W.; Jiang, W.; Zhu, W. Losartan protects against osteoarthritis by repressing the TGF-β1 signaling pathway via upregulation of PPARγ. J. Orthop. Transl. 2021, 29, 30–41. [CrossRef]

195. Bao, J.-P.; Chen, W.-P.; Feng, J.; Hu, P.-F.; Shi, Z.-L.; Wu, L.-D. Leptin plays a catabolic role on articular cartilage. Mol. Biol. Rep. 2009, 37, 3265–3272. [CrossRef]

196. Stevens, A.L.; Wheeler, C.A.; Tannenbaum, S.R.; Grodzinsky, A.J. Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants. Osteoarthr. Cartil. 2008, 16, 489–497. [CrossRef]

197. Madzuki, I.N.; Lau, S.F.; Abdullah, R.; Ishak, N.I.M.; Mohamed, S. Vernonia amygdalina inhibited osteoarthritis development by anti-inflammatory and anticonagglene pathways in cartilage explant and osteoarthritis-induced rat model. Phytother. Res. 2019, 33, 1784–1793. [CrossRef]

198. Pérez-García, S.; Carrión, M.; Gutiérrez-Cañas, I.; González-Álvaro, I.; Comzariz, R.P.; Juarranz. Y. VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts. J. Cell. Mol. Med. 2016, 20, 678–687. [CrossRef]

199. Najari, M.; Ouhaddi, Y.; Paré, F.; Lussier, B.; Urade, Y.; Kapoor, M.; Pelletier, J.; Martel-Pelletier, J.; Bendorer, M.; Fahmi, H. Role of Lipocalin-Type Prostaglandin D Synthase in Experimental Osteoarthritis. Arthritis Rheumatol. 2020, 72, 1524–1533. [CrossRef]

200. Attur, M.; Al-Mussawir, H.E.; Patel, J.; Kitay, A.; Dave, M.; Palmer, G.; Pillinger, M.H.; Abramson, S.B. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: Evidence for signaling via the EPI receptor. J. Immunol. 2008, 181, 5082–5088. [CrossRef] [PubMed]

201. Gossel, M.; Berenbaum, F.; Salvat, C.; Sautet, A.; Pigenet, A.; Tahiri, K.; Jacques, C. Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: Possible influence on osteoarthritis. Arthritis Care Res. 2008, 58, 1399–1409. [CrossRef] [PubMed]

202. Kesteloot, F.; Desmoulière, A.; Leclercq, I.; Thiry, M.; Arrese, J.E.; Prockop, D.J.; Lapière, C.M.; Nusgens, B.V.; Colige, A. ADAM metalloproteinase with thrombospondin type 1 motif 2 inactivation reduces the extent and stability of bone tetra-chloride-induced hepatic fibrosis in mice. Hepatology 2007, 46, 1620–1631. [CrossRef] [PubMed]

203. Bukong, T.N.; Maurice, S.; Chahal, B.; Schaeffer, D.F.; Winwood, P. Versican: A novel modulator of hepatic fibrosis. Lab. Investig. 2016, 96, 361–374. [CrossRef]

204. Yao, Y.; Hu, C.; Song, Q.; Li, Y.; Da, X.; Yu, Y.; Li, H.; Clark, I.M.; Chen, Q.; Wang, Q.K. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc. Res. 2019, 116, 956–969. [CrossRef]

205. Yang, N.; Zhang, Q.; Ye, S.; Lu, T.; Sun, M.; Wang, L.; Wang, M.; Pan, Y.; Dang, S.; Zhang, W. Adamts18 Deficiency Causes Spontaneous SMG Fibrogenesis in Mice. J. Dent. Res. 2021, 101, 226–234. [CrossRef]

206. Mittaz, L.; Ricardo, S.; Martinez, G.; Kola, I.; Kelly, D.J.; Little, M.H.; Hertzog, P.; Pritchard, M.A. Neonatal calyceal dila-tion and renal fibrosis resulting from loss of Adamts-1 in mouse kidney is due to a developmental dysgenesis. Nephrol. Dial. Transplant. 2005, 20, 419–423. [CrossRef]

207. Huang, Y.Z.; Zhao, L.; Zhu, Y.; Tian, S.J.; Zhang, W.; Liu, S.; Ge, J.F. Interrupting TGF-β1/CCN2/integrin-α5β1 signaling alleviates high mechanical-stress caused chondrocyte fibrosis. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 1233–1241. [CrossRef]

208. Wang, X.; Tan, J.; Sun, J.; Fang, P.; Chen, J.; Yuan, W.; Chen, H.; Liu, Y. Transcripomics Study to Determine the Molecular Mechanism by which sIL-13Rα2-Fc Inhibits Caudal Intervertebral Disc Degeneration in Rats. BioMed Res. Int. 2020, 2020, 76458988. [CrossRef]

209. Mann, C.J.; Bradley, A.M.; Jones, E.R.; McNamara, I.R.; Smith, T.O.; Riley, G.P. Stiffness post-total knee replacement: A proof of principle study investigating the effect of gene expression analysis of markers of fibrosis. Arthritis Care Res. 2014, 67, 701–712. [CrossRef] [PubMed]

210. Hunter, D.J.; Birmer-Beinstra, S. Osteoarthritis. Lancet 2019, 393, 1745–1759. [CrossRef]

211. Block, J. Osteoarthritis: OA guidelines: Improving care or merely codifying practice? Nat. Rev. Rheumatol. 2014, 10, 324–326. [CrossRef] [PubMed]

212. Higashi, H.; Barendregt, J.J. Cost-Effectiveness of Total Hip and Knee Replacements for the Australian Population with Osteoarthritis: Discrete-Event Simulation Model. PloS ONE 2011, 6, e25403. [CrossRef] [PubMed]

213. Ruiz, D., Jr.; Koenig, D.; Dall, T.M.; Gallo, P.; Narzukil, A.; Parvizi, J.; Tongue, J. The Direct and Indirect Costs to Society of Treatment for End-Stage Knee Osteoarthritis. J. Bone Jt. Surg. 2013, 95, 1473–1480. [CrossRef] [PubMed]

214. Valero, P.; Dalal, K. ADAMTS-4 and ADAMTS-5: Key enzymes in osteoarthritis. J. Cell. Biochem. 2011, 112, 3507–3514. [CrossRef]

215. Kramerova, I.; Kawaguchi, N.; Fessler, L.; Nelson, R.; Chen, Y.; Kramerov, A.; Kusche-Gullberg, M.; Kramer, J.; Ackley, B.; Sieron, A.L.; et al. Papilin in development; a pericellular protein with a homology to the ADAMTS metalloproteinases. Development 2000, 127, 5475–5485. [CrossRef]

216. Zhong, S.; Khalil, R.A. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease. Biochem. Pharmacol. 2019, 164, 188–204. [CrossRef]

217. Kador, K.E.; Lightfoot, S.J.; Watson, R.B. Procollagen N-peptidases: Procollagen N-proteinases. Methods Enzymol. 1995, 248, 756–771. [CrossRef]

218. Wang, W.-M.; Ge, G.; Lim, N.H.; Nagase, H.; Greenspan, D.S. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem. J. 2006, 398, 515–519. [CrossRef]
220. Chijiiwa, M.; Mochizuki, S.; Kimura, T.; Abe, H.; Tanaka, Y.; Fujii, Y.; Shimizu, H.; Enomoto, H.; Toyama, Y.; Okada, Y. CCN1 (Cyr61) Is Overexpressed in Human Osteoarthritic Cartilage and Inhibits ADAMTS-4 (Aggrecanase 1) Activity. *Arthritis Rheumatol.* 2015, 67, 1557–1567. [CrossRef] [PubMed]

221. Jang, G.; Lee, S.A.; Hong, J.H.; Park, B.-R.; Kim, D.K.; Kim, C.S. Chondroprotective Effects of 4,5-Dicaffeoylquinic Acid in Osteoarthritis through NF-κB Signaling Inhibition. *Antioxidants* 2022, 11, 487. [CrossRef] [PubMed]

222. Zhang, H.; Bei, M.; Zheng, Z.; Liu, N.; Cao, X.; Xiao, Y.; Lian, Q.; Wang, Y.; Hou, X.; Tian, F. Parathyroid Hormone (1–34) Attenuates Cartilage Degradation and Preserves Subchondral Bone Micro-architecture in Rats with Patella Baja-Induced-Patellofemoral Joint Osteoarthritis. *Calcif. Tissue Res.* 2022, 111, 87–95. [CrossRef] [PubMed]

223. Li, H.; Gou, Y.; Tian, F.; Zhang, Y.; Lian, Q.; Hu, Y.; Zhang, L. Combination of metformin and exercise alleviates osteoarthritis in ovariectomized mice fed a high-fat diet. *Bone* 2022, 157, 116323. [CrossRef]

224. Han, J.; Guan, J.; Zhu, X. β-Ecdysone attenuates cartilage damage in a mouse model of collagenase-induced osteoarthritis via mediating FOXO1/ADAMTS-4/5 signaling axis. *Histol Histopathol* 2021, 36, 785–794. [CrossRef]

225. Santamaria, S.; Cuffaro, D.; Nuti, E.; Ciccone, L.; Tuccinardi, T.; Liva, F.; D’Andrea, F.; de Groot, R.; Rossello, A.; Ahnström, J. Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide. *Sci. Rep.* 2021, 11, 949. [CrossRef]

226. Gilbert, A.M.; Bursavich, M.G.; Lombardi, S.; Georgiadis, K.E.; Reifenberg, E.; Flannery, C.R.; Morris, E.A. 5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. *Bioorganic Med. Chem. Lett.* 2007, 17, 1189–1192. [CrossRef]

227. Santamaria, S.; Buemi, F.; Nuti, E.; Cuffaro, D.; De Vita, E.; Tuccinardi, T.; Rossello, A.; Howell, S.; Mehmoood, S.; Snijders, A.P.; et al. Development of a fluorogenic ADAMTS-7 substrate. *J. Enzym. Inhib. Med. Chem.* 2021, 36, 2160–2169. [CrossRef]

228. Guo, F.; Lai, Y.; Tian, Q.; Lin, E.A.; Kong, L.; Liu, C.-J. Granulin-epithelin precursor (GEP) binds directly to ADAMTS-7 and ADAMTS-12 and inhibits their degradation of cartilage oligomeric matrix protein. *Arthritis Care Res.* 2010, 62, 2023–2036. [CrossRef]

229. Santamaria, S.; Martin, D.R.; Dong, X.; Yamamoto, K.; Apte, S.S.; Ahnström, J. Post-translational regulation and proteolytic activity of the metalloproteinase ADAMTS8. *J. Biol. Chem.* 2021, 297, 101323. [CrossRef]

230. He, D.; Wang, J.; Li, Y.; Wu, G.; Zhu, G.; Chen, L. Low-intensity pulsed ultrasound promotes aggrecan expression via ZNT-9 in temporomandibular joint chondrocytes. *Gene* 2020, 768, 145318. [CrossRef] [PubMed]

231. He, D.; An, Y.; Li, Y.; Wang, J.; Wu, G.; Chen, L.; Zhu, G. RNA sequencing reveals target genes of temporomandibular joint osteoarthritis in rats after the treatment of low-intensity pulsed ultrasound. *Gene* 2018, 672, 126–136. [CrossRef] [PubMed]